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ABSTRACT
Perioperative myocardial ischemia and infarction are frequent and serious 
complications, especially in elderly patients with cardiovascular risk 
factors who are undergoing major non-cardiac surgery. As the population 
perioperative cardiac complications will likely increase in the future.  The 
objectives of this study were to determine the incidence and prognosis of 
perioperative myocardial infarction in patients undergoing non-cardiac 
surgery in a Finnish tertiary care hospital, to investigate the pathophysiology 
of this complication, and to review the current literature for preventive 
strategies.
Material and methods
Study I was a prospective observational study that investigated the incidence 
and 90-day mortality of perioperative myocardial infarction in 385 patients, 
aged 50 years or older, undergoing non-cardiac surgery in Meilahti Hospital. 
The performance of the Gupta cardiac risk calculator in non-American 
patient population was tested as well. Study II investigated the incidence 
of postoperative myocardial ischemia and its potential association with 
development of myocardial infarction. The prospective cohort included 
51 high cardiac risk patients undergoing vascular surgery. The patients 
were postoperatively monitored with continuous electrocardiography and 
cumulative ischemic load was calculated. Study III aimed to further expand 
the current knowledge of the pathophysiology of perioperative myocardial 
perioperative endothelial glycocalyx injury with development of perioperative 
myocardial infarction. Study IV was a systematic review and meta-analysis 
protection. The review included 3 studies and 196 patients.
11
Results
The incidence of perioperative myocardial infarction was 7%, and it was 
calculator performed fairly in predicting myocardial infarction. Postoperative 
ischemic electrocardiographic changes were common in high cardiac risk 
patients, with an incidence of 33%. Despite being mostly asymptomatic, 
cumulative ischemic load predicted perioperative myocardial infarction 
by elevated plasma interleukin-6 levels, was associated with perioperative 
troponin release and myocardial infarction. None of the measured endothelial 
glycocalyx injury markers (soluble thrombomodulin, syndecan-1, and vascular 
adhesion protein-1) was associated with perioperative myocardial infarction. 
Intravenous esmolol reduced the incidence of perioperative myocardial 
ischemia (RR =0.43, 95% CI: 0.21-0.88). No association with clinically 
included in the review were too few and too small to provide conclusive 
evidence regarding other clinically relevant outcomes, such as mortality.
Conclusions
Based on the data of the two prospective patient cohorts from a large Finnish 
tertiary care hospital, perioperative myocardial ischemia and infarction are 
frequent complications in surgical patients and are associated with poor 
prognosis. Without systematic perioperative ischemia monitoring, most 
of these complications remain undiagnosed. Future studies are needed to 
determine the pathophysiological mechanisms of perioperative myocardial 
Keywords
Perioperative myocardial infarction, myocardial ischemia, non-cardiac surgery, 
cardiac troponin T, endothelial glycocalyx, prevention, esmolol
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INTRODUCTION
Developments in surgical techniques, anesthesiology and perioperative 
care have improved postoperative outcome and survival of patients during 
the past decades. Thanks to the modern less invasive surgical techniques, 
elderly patients with several comorbidities can today be operated on to 
achieve more quality life years. However, major surgery may also precipitate 
to complications, perhaps the most underdiagnosed, yet potentially severe, 
of which are cardiovascular adverse events. Each year more than 10 million 
(Kristensen et al., 2014; Botto et al., 2014), and these complications account 
for at least one third of perioperative deaths (Botto et al. 2014; Kazaure et al. 
2013; MacFalls et al., 2008). Furthermore, perioperative cardiac complications 
medical care (Udeh et al., 2014). As the Western population is rapidly ageing, 
cardiac complications will likely increase in the future.
Perioperative myocardial infarction (PMI) is the most severe perioperative 
cardiac complication, with a mortality rate of 20-40% (Devereaux et al., 
2005; Devereaux et al., 2011; Davenport et al., 2007; Ghaferi et al., 2009). The 
observed incidence of PMI depends on the patient population, type of surgery, 
and perioperative surveillance method used. Large studies with prospective 
ischemia monitoring have shown incidence rates of 5-7% for PMI (Botto et al., 
2014; Devereaux et al. 2011; Devereaux et al., 2008; Nagele et al., 2013; van 
Waes et al., 2013; Badner et al., 1998). However, retrospective, register-based 
studies have reported incidences of less than 1% (Udeh et al., 2014; Menendez 
et al.
and diagnostics. According to today’s practice, most patients return to 
surgical wards within hours of surgery and thereafter their vital parameters 
are monitored at four to eight hours’ intervals in contrast to continuous 
intraoperative monitoring. Furthermore, postoperative analgesic medication 
and primary diseases, such as diabetes, blunt of the patient awareness and 
mask cardiac symptoms. Because of this, timely diagnosis and appropriate 
treatment of perioperative myocardial ischemia are challenging. Therapeutic 
guidelines designed for nonoperative myocardial infarction (MI) are not 
directly applicable because of the potential risk of postoperative bleeding. 
However, especially patients with cardiovascular risk factors, i.e. advanced 
monitoring to detect and treat earlier hemodynamic disturbances, such as 
tachycardia, hypotension and hypoxemia, shown to increase the risk for 
myocardial ischemia (Mauermann et al., 2016). Further studies are needed 
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surgery patients with postoperative troponin elevation and demonstrated 
adverse cardiac outcomes. However, the patients whose treatment remained 
 
perioperative myocardial ischemia. Because the treatment of PMI is complex, 
prevention seems an appropriate strategy and it has been investigated in 
several large-scale studies (Devereaux et al., 2008; Devereaux et al., 2014; 
Devereaux et al., 2014). More recently, anticoagulants alone or combined with 
aspirin have been shown to be effective in reducing adverse cardiovascular 
events in high cardiac risk surgical patients (Devereaux et al., 2018; Steffel et 
treatments remain limited and widely adapted recommendations do not exist. 
Despite general advancements in perioperative care, mortality associated 
with PMI is still close to that observed 30 years ago (von Knorring, 1981). 
Furthermore, the exact pathophysiological mechanisms of perioperative 
myocardial ischemia are unclear. 
Accordingly, the aims of this study were to elucidate the clinical picture 
and prognosis of PMI in a Finnish tertiary care university hospital, and to 
determine how a modern cardiac risk index (Gupta et al., 2011) performs in 
predicting PMI in the particular patient cohort. Moreover, this thesis aimed 
acute endothelial injury and their association with development of PMI. 
Finally, this thesis included a systematic review and meta-analysis that aimed 
beta-blocker esmolol in perioperative cardiac protection. 
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REVIEW OF THE LITERATURE
CARDIAC SURGERY
association with postoperative outcome date back to 1952, when PMI was 
reported incidence rates of 0.1% to 37% for PMI, depending on the patient 
population being studied. In the general population, PMI is rare, early studies 
reported an incidence of 0.1% to 0.7% (Tarhan et al., 1972; Plumlee and 
Boettner, 1972) which corresponds to today’s observations (Udeh et al., 
2014; Menendez et al., 2015). However, in high-risk patients the incidence 
of PMI is substantially higher, with studies from the 1960s to the 1980s 
showing that 1.9% to 37% of patients with CAD and previous myocardial 
infarction had a PMI in non-cardiac surgery (Tarhan et al., 1972; Rao et al., 
1983; Goldman et al., 1977; Steen et al., 1978). Different types of surgeries 
carry a different cardiac risk. As early as in 1961, Driscoll and colleagues 
observed that patients with peripheral vascular disease were at a higher risk 
of sustaining PMI than the general population (Driscoll et al., 1961). 
and according to these studies the incidence of PMI in vascular surgery 
patients is 1% to 15% (McFalls et al., 2008; Boucher et al., 1985; Brown et 
al., 1981; Hertzer, 1982; Yang et al., 2006). This is likely related to the burden 
(Sukhija et al., 2004). Furthermore, surgery-related factors, such as clamping 
the arteries, bleeding, and a potentially prolonged operation with unstable 
hemodynamics, add to the increased cardiac risk. 
In Finland, the incidence rates of PMI are similar to those observed 
in other Western countries. In 1981, von Knorring published the results 
of a prospective observational study of 12 654 patients undergoing non-
cardiac surgery and reported an incidence of 1.8% for PMI. However, when 
214 patients from the same cohort with previous myocardial infarction or 
electrocardiographic patterns suggesting myocardial strain were re-examined 
with systematic electrocardiography (ECG) monitoring at the time of their 
next operation, 17.7% of the patients were diagnosed with PMI, being fatal in 
32% (von Knorring, 1981). This study still remains the largest investigating 
the incidence of PMI in Finnish non-cardiac surgery patients, but most likely 
been made in the diagnostics and treatment of CAD. Since 1981, several 
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observational single-center studies investigating cardiac complications in 
non-cardiac surgery in Finland have emerged (Hietala et al., 2014; Utriainen 
et al., 2014; Hietala et al., 2013; Scheinin et al., 2000; Backlund et al., 1999; 
Backlund et al., 1999; von Knorring et al., 1992). However, all of the studies 
in clinically relevant patient-centered outcomes, and currently, no national 
guidelines exist regarding the perioperative monitoring or follow-up of 
patients with increased cardiac risk. 
Perioperative myocardial ischemia, detected by continuous ECG monitoring, 
transesophageal echocardiography, cardiokymography, or changes in the 
blood lactate levels, gained researchers’ attention in 1980. Early studies 
focused on intraoperative myocardial ischemia and reported incidence 
rates of 18% to 78% in patients with pre-existing CAD (London et al., 1988; 
Stone et al., 1988; Haggmark et al., 1989). In 1990, monitoring started to 
the relation of perioperative myocardial ischemia to postoperative outcome 
emerged. These studies showed that perioperative myocardial ischemia occurs 
most commonly postoperatively, (Mangano et al., 1990) is silent in nature 
(Frank et al., 1990; Ganz  et al., 1994), and is associated with postoperative 
cardiac complications (Frank et al., 1990; Ganz et al., 1994; Landesberg et al., 
1993; Landesberg et al., 2001). However, debate continues about whether and 
how the potential perioperative myocardial ischemia should be monitored 
and whether treatment of ischemia can improve postoperative outcome. 
Table 1 summarizes the studies investigating perioperative myocardial 
ischemia and its impact on postoperative outcome.
Table 1.






























































































Myocardial injury in non-cardiac surgery 
The latest update on the sequelae of perioperative cardiac morbidity 
MINS as a myocardial injury that may or may not result in necrosis, has 
based on the prospective analysis of the perioperative clinical data of over 
15 000 patients (Botto et al., 2014). The introduction of MINS expanded 
previous knowledge of perioperative cardiac complications by showing 
that a mere perioperative cardiac biomarker release, irrespective of other 
ischemic features, is associated with substantial cardiovascular morbidity 
and mortality (Devereaux et al., 2017). Puelacher et al.
this observation in a separate cohort of patients. It remains unclear, however, 
by which treatment. Currently, several trials targeting both MINS prevention 
and treatment are underway; results can be expected in the near future.
Morbidity and mortality 
Since the initial observation of perioperative cardiac complications, it was 
clear that a substantial mortality is associated with these events. Studies 
from the early 1990s reported a mortality of 36% to 70% associated with 
PMI (Mangano, 1990; Mangano et al., 1990; Mangano et al., 1991; Raby et 
al., 1992). More recently, mortality rates of 12% to 40% have been reported 
(Devereaux et al., 2011; Davenport et al., 2007; Ghaferi et al., 2009; Devereaux 
et al., 2005). The decreased mortality may be the result of overall improved 
perioperative care, including patient selection, preoperative optimization and 
improved management of perioperative complications. However, patients 
with PMI still have a tenfold 30-day mortality relative to patients without 
PMI (Redfern et al
demonstrated that even a minor perioperative cardiac troponin release is 
associated with increased mortality. For example, Devereaux and colleagues 
showed that a troponin T (TnT) release of 0.02 ng/mL had an adjusted hazard 
ratio (aHR) of 2.41 (95% CI: 1.33-3.77) for 30-day mortality compared with 
a TnT concentration of 0.01 ng/mL or less. Higher concentrations of 0.02-
0.029 ng/mL and >0.03 ng/mL had aHRs of 5 (95% CI 3.72-6.76) and 10.48 
(95% CI 6.25-16.62), respectively. Mortality rates for TnT concentrations 
of 0.01, 0.02, 0.02-0.029, and >0.03 were 1.0,% 4.0%, 9.3%, and 16.3% 
(Devereaux et al., 2012).
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in intensive care unit (ICU), and timely management of hemodynamical 
disturbances were suggested for high cardiac risk patients undergoing 
non-cardiac surgery (Rao et al
monitoring, high cardiac risk patients are today most commonly monitored 
in the same manner as the general surgical population and postoperative 
cardiac complications remain underdiagnosed and inadequately managed.
BASIC PATHOPHYSIOLOGY OF PERIOPERATIVE MYOCARDIAL 
INFARCTION
Despite years of research, the exact pathophysiological mechanisms of 
perioperative cardiac complications are still generally poorly understood. 
Surgery and anesthesia are associated with activation of the sympathetic 
bleeding and hypothermia, all of which are elements that destabilize a 
previously balanced CAD and can trigger cardiac complications. Data from 
several perioperative hemodynamic studies suggest that tachycardia precedes 
ischemic episodes (Biccard and Rodseth, 2010) and is today a generally 
recognized element in the pathophysiology of perioperative cardiac ischemia. 
In addition, according to the current evidence coronary hypoperfusion and 
thrombus formation may play a key role in this pathophysiological process. 
22
Studies conducted in the 1980s, in which the diagnosis was set based on 
repeated postoperative ECG recordings, suggested that PMIs occur on the 
second or third postoperative day. Moreover, the earlier studies generally used 
creatine phosphokinase (CK) as the biomarker of cardiac injury. Especially 
at the beginning, the laboratory analysis of this biomarker was slow, and 
muscles, brain, and several other tissues (Rosalki et al., 2004). Today, with 
cardiac troponins being the most commonly used biomarkers, most PMIs 
 et al., 1998; 
Gandhi et al., 2006). 




 et al., 2012), with type 1 and type 2 being 
predominant in the non-cardiac operative setting. 
Figure 2 demonstrates the difference between type 1 and type 2 MIs. 
Figure 2.
Classically, the majority of PMIs have been considered to be of type 2, 
however, recent post-mortem and angiographic studies have shown that the 
thought (Gualandro et al., 2012).
24
Type 1 MI is an event related to atherosclerotic plaque rupture, ulceration, 
or dissection that results in intraluminal thrombus in one or more coronary 
platelet emboli with ensuing myocyte necrosis (Thygesen et al., 2012). Of 
fatal MIs in nonoperative settings, 70% are associated with coronary plaque 
rupture and usually patients present with severe CAD. However, on occasion 
(5-20% of cases) only mild to moderate or no CAD is found in coronary 
angiography, especially in women (Thygesen et al., 2012). Post-mortem and 
angiographic studies have shown that in 40% to 50% of patients sustaining 
fatal PMI either atherosclerotic plaque rupture or coronary thrombus is 
present (Cohen and Aretz, 1999; Duvall et al., 2012). Thus, although type 
2 MI might dominate in the perioperative setting, the difference is not as 
Established CAD with complex coronary lesions appears to be an important 
predisposing factor for PMI. Fatal PMIs due to an atherosclerotic plaque 
(Cohen and Aretz, 1999; Dawood et al., 1996). However, of all PMIs only 7% 
have the etiology of ruptured atherosclerotic plaque and subsequent coronary 
thrombus (Gualandro et al., 2012). Thus far, the only study comparing 
nonoperative and perioperative MIs was published by Gualandro and 
with PMI had angiographic evidence of complex coronary lesions suggestive 
of type 1 MI, compared with 57% of the patients with non-operative MIs. 
Notably, even in the presence of clear coronary obstruction only 40% of 
patients with PMI had typical ischemic symptoms (Gualandro et al., 2012).
To summarize, in light of the current evidence type 1 MI appears to be 
somewhat less common than type 2 MI in the operative setting. However, the 
difference between the incidences might not be as clear as previously thought. 
Furthermore, the current histological observations may not be totally accurate 
since patients with PMI are generally referred for coronary angiography 
 et al., 
2012). This may result in prolonged exposure to antiplatelet or anticoagulant 
agents or potentially spontaneous resolution of thrombi. 
Type 2 MI is an event related to a condition other than plaque rupture that 
causes an imbalance between myocardial oxygen supply and demand. Type 
2 MI may occur in critically ill or in patients undergoing major non-cardiac 
surgery when factors such as endogenous or exogenous catecholamines, 
endothelial dysfunction, coronary vasospasm, tachycardia, and hypertension 
or hypotension cause both an increased myocardial oxygen demand and a 
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According to the post-mortem studies, approximately 50% of fatal PMIs 
are caused by myocardial oxygen supply-demand imbalance (Cohen and 
Aretz, 1999; Dawood et al., 1996). Fatal PMIs caused by myocardial oxygen 
supply-demand imbalance predominate in the early (days one to four) 
postoperative period (Cohen and Aretz, 1999). Similarly to type 1 MIs, 
the development of type 2 PMI (Ellis et al., 1996). However, in the operative 
setting the site of MI does not necessarily depend on the site of critical 
stenoses (Poldermans et al., 2001), supporting the hypothesis that the 
pathophysiology of PMI differs from that of nonoperative MI. Furthermore, 
the majority of perioperative myocardial ischemia and MIs are of non-ST-
segment elevation type. Perioperative ischemic events are usually transient 
but especially if prolonged, may lead into cardiac biomarker release and 
development of PMI (Landesberg et al., 1993). Hemodynamic studies have 
demonstrated that an increase in heart rate or relative tachycardia usually 
precedes perioperative ischemic events (Fleisher et al., 1995; Landesberg et 
al., 2002). Other important aspect is that, unlike in a nonoperative setting, 
where hypertension and subsequent left ventricular enlargement have been 
shown to predict coronary plaque rupture, (Heidland and Strauer, 2001), 
hypotension is more commonly associated with adverse perioperative cardiac 
outcomes (Charlson et al., 1989; Sprung et al., 2000).
To summarize, the development of type 2 MI in non-cardiac surgery 
seems to be due to a complex interplay between pre-existing risk factors, 
and hypercoagulability state. These mechanisms warrant further investigation 
to elucidate the pathophysiology of PMI.
Summary of pathophysiological mechanisms
Understanding the pathophysiological mechanisms of PMI is essential in 
order to develop appropriate prevention and treatment strategies. Based on 
the discussed studies, the following factors are probably responsible for the 
development of PMI: First, PMI is most likely to occur in patients with CAD 
or with several risk factors for CAD. Second, hemodynamic disturbances, 
namely tachycardia and/or hypotension, typical for intraoperative and 
mediated hypoperfusion, further aggravated by coronary thrombus secondary 
at least mild to moderate anemia postoperatively because of bleeding and 
dilution, and this further decreases the oxygen supply. Finally, myocardial 
oxygen demand is perioperatively increased because of pain, shivering, and 
sympathetic activation.
It is unknown by which mechanisms coronary occlusions occur in 
Virchow’s triad is the classic model describing the factors predisposing to 
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and coagulation (Lowe, 2004). According to this, the following key elements 
have been suggested in a review article by Biccard and Rodseth (2010). 
First, the pre-existing non-critical coronary stenoses, together with 
due to a decreased blood velocity associated with a fall in the pressure 
creates conditions favorable for thrombus formation. The cascade is initiated 
by platelet activation that occurs in high shear stress conditions, i.e. at the 
apex of stenosis. Activated platelets interact with each other causing platelet 
count to increase and platelet activation to rise exponentially. On entering 
the post-stenotic recirculation zone platelets are exposed to a low shear 
stress milieu, allowing cellular interaction and thrombus formation to take 
place (Biccard and Rodseth, 2010). Thrombus formation is further enhanced 
by changes in red blood cells and the endothelial glycocalyx and expression 
of coagulation factors. In the recirculation region, red blood cells undergo 
clumping and interact with both platelets and neutrophils, contributing to 
thrombus formation (Goel and Diamond, 2002). 
Furthermore, at the location of the post-stenotic low shear stress zone, 
cytokines, increasing the expression of adhesion molecules, such as vascular 
adhesion molecule (V-CAM), intracellular adhesion molecule (I-CAM), and 
E-selectin, while down-regulating the production of endothelial nitric oxide 
synthetase (eNOS), prostacyclin, and tissue plasminogen activator (tPA) – 
factors all resulting in increased thrombogenicity (Biccard and Rodseth, 
2010). Finally, in the postoperative period, there is a rise in all coagulation 
 et al., 2006), 
increasing plasma viscosity, platelet aggregation, and platelet sensitivity 
to catecholamines. At the same time, coagulation inhibitors appear to be 
decreased, probably due to dilution or impaired synthesis (Longhitano et 
al., 2006). 
In summary, pre-existing coronary stenoses together with perioperative 
low shear stress, ideal for platelet and endothelial activation and initiation 





ENDOTHELIAL GLYCOCALYX IN CARDIAC DISEASE
The glycocalyx, comprising glycoproteins, proteoglycans, and soluble proteins, 
coats the endothelium of all healthy vasculature. The presence of this structure 
of its physiological role began in 1970 (Desjardins and Duling, 1990). The 
endothelial glycocalyx (EG) was long regarded as a selective but static physical 
barrier maintaining vascular wall permeability and this was supported by 
Starling’s law of capillary exchange in 1896 (Levick and Michel, 2010). Today, 
it is evident, however, that EG is a dynamic biochemical structure that in 
physiological conditions regulates vascular permeability, cellular interactions, 
Figure 3A presents the basic structure of normal EG. 
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Proteoglycans and glycoproteins anchor the glycocalyx to the endothelium 
and form an extensive matrix containing soluble plasma components (Pillinger 
and Kam, 2017). Proteoglycans have a protein core to which negatively charged 
glycosaminoglycan (GAG) side chains are attached. The proteoglycan core 
proteins may be attached to the endothelial cell membrane (e.g. glypicans) or 
have a transmembrane domain that links to the endothelial cell cytoskeleton 
(e.g. syndecans), while the GAG chains extend into the extracellular space 
(Tarbell and Cancel, 2016). Heparan sulfate (HS), chondroitin sulfate (CS), 
and hyaluronan (HA) are the dominant GAGs on most cell surfaces (Tarbell 
and Cancel, 2016). The GAG chains carry strong negative charge and are 
hydrophilic. Glycoproteins are glycoconjugates in which a core protein 
carries one or more glycans covalently attached to a polypeptide backbone. 
Common examples of glycoproteins are endothelial cell surface receptors that 
(E and P), integrins, and members of the immunoglobulin superfamily (e.g. 
I-CAM and V-CAM) (Tarbell et al., 2014). The EG interacts with several soluble 
plasma constituents, such as proteins (e.g. albumin), growth factors and ions 
forming a dynamic, physiologically active layer known as the endothelial 
surface layer (ESL) (Tarbell and Cancel, 2016). The entire makeup of the 
ESL continuously changes with a process of destruction and re-synthesis 
within the ESL (Reitsma et al., 2007).
As a complex and active composite of inert glycocalyx and bound plasma 
constituents, ESL plays an important role in several physiological processes. 
walls. The process is regulated at the site at which it begins in the capillary 
network, and ESL tightly controls the oncotic pressure differences between 
(Becker et al
regulates cellular interactions by repelling red blood cells (Reitsma et al., 
2007) and attenuating the interactions of platelets and leukocytes (Becker et 
(Pries et al., 2000). Increased shear stress activates ESL to produce nitric 
oxide (NO) which causes vasodilatation and reduces shear stress (Jacob et al., 
2007). Furthermore, ESL protects the endothelial cells from oxidative stress 
through its capacity to bind enzymes that scavenge oxygen radicals (Reitsma 
et al., 2007) Finally, ESL binds several ligands and enzymes facilitating 
et al., 2007), and 
important anticoagulant mediators such as antithrombin III (Alphonsus 
and Rodseth, 2014). The endothelium also participates in the production 
of anticoagulant mediators itself, and functional endothelium and ESL are 
essential in maintaining homeostasis in coagulation and anticoagulation. 
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As EG interacts and dynamically reacts to the different circulating plasma 
constituents and physiological changes, it may shed or destroy under a variety 
of conditions. Figure 3B demonstrates the rearrangement and shedding of 
EG following a noxious stimulus.  
Figure 3B.
-
Endothelial glycocalyx injury can vary from relatively minor perturbations 
to a complete dissolution of the layer. Any damage can lead to adverse 
consequences such as increased vascular wall permeability and interstitial 
edema, attenuated vascular responses to shear stress, platelet aggregation, 
leukocyte adhesion, altered microvascular blood viscosity and generation of 
prothrombotic milieu. Furthermore, these adverse alterations of physiology 
have been shown to be associated with a variety of diseases. For example, 
normal renal function depends upon an intact glycocalyx, and atherogenesis 
seems to be associated with glycocalyx injury (Alphonsus and Rodseth, 2014). 
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Pathological injury to EG may occur in a several clinical conditions. Thus 
far, our knowledge of the pathophysiological mechanisms leading to EG injury 
Ischemia-reperfusion (I/R) injury. A marked decrease in the endothelial 
glycocalyx GAG chain volume has been observed after I/R (Mulivor and 
Lipowsky, 2004). EG destruction related to I/R may particularly be a concern 
in cardiac surgery since this impairs endothelial-dependent coronary 
edema (Chappell et al., 2009). In fact, cardiac surgery itself has been shown to 
predispose to EG diminution, independently from I/R, as shown by Bruegger 
et al. (2009). EG injury following I/R is not solely restricted to the heart, but 
concerns also other vital organs, such as the liver and kidneys (Park et al., 
2010; Snoeijs et al., 2011).
Sepsis and trauma. 
factor alpha 
include C-reactive protein (CRP), adenosine, bradykinin, and bacterial 
lipopolysaccharide (Pillinger and Kam, 2017). The absolute plasma level 
of syndecan-1 has been shown to correlate with severity of sepsis, dismal 
prognosis and need for intubation in septic shock patients (Puskarich et 
al., 2016). Because of the generalized nature of septic disease, studies have 
focused on measuring the leaked EG components from plasma, rather than 
Hypervolemia. Fluid volume overload can independently cause endothelial 
shedding. When colloid solutions are infused in normovolemic patients, 
approximately 60% of colloid almost immediately extravasates into the 
interstitial space (Pillinger and Kam, 2017). Furthermore, atrial natriuretic 
peptide (ANP) has direct adverse effects on glycocalyx integrity.  ANP is 
causes a rapid shedding of glycocalyx via a cyclic-GMP-linked proteolytic 
pathway (Bruegger et al., 2005).
Blood volume loss. Like hypervolemia, also hypovolemia, or more accurately 
severe bleeding, has been shown to cause glycocalyx shedding. Current 
observations are based on animal studies. Kozar et al. (2011) demonstrated 
and subsequent severe hypotension (mean arterial pressure of 30 mmHg in 
90 minutes). The changes were partially restored with plasma resuscitation, 
but not when crystalloids were used. In another study by Torres Filho et al. 
(2013), a 40% reduction in circulating blood volume caused a 59% reduction 
in glycocalyx thickness. Based on these in vitro observations, EG injury has 
been suggested to play a key role in the development of hemorrhagic shock. 
Hyperglycemia. Both acute and chronic hyperglycemias have been shown to 
damage the glycocalyx. During acute hyperglycemia a reduction in glycocalyx 
volume and an increased glycocalyx permeability have been demonstrated 
in both animal (Zuurbier et al., 2005) and clinical studies (Nieuwdorp et al., 
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2006). Both of the forementioned studies concluded that hyaluronans, critical 
in maintaining the glycocalyx integrity, seem to be the vulnerable component 
during acute hyperglycemia. Clinical studies investigating diabetic patients 
have shown that these patients lose approximately half to three-quarters 
of their systemic glycocalyx volume compared with age-matched controls 
(Nieuwdorp et al., 2006). Furthermore, shedding of the glycocalyx has been 
postulated to be associated with development of microalbuminuria (Singh 
et al., 2011). The exact mechanisms connecting hyperglycemia and EG injury 
remain unknown. Reactive oxygen species disrupting hyaluronan binding to 
the glycocalyx, modulation of the sulfation of GAG chains, and a decrease in 
the number of GAG chains have been hypothesized to be the key elements 
(Lemkes et al., 2012).
atherogenesis has been considered by many to be dependent on the 
accumulation of lipids within the artery wall. Today, however, it is evident 
that the pathology of atherosclerosis is far more complicated than previously 
supposed. Despite changes in lifestyle and the use of cholesterol-lowering 
medication, cardiovascular diseases continue to be the leading cause of 
death in developed countries (Braunwald, 1997). Based on numerous 
pathophysiological observations, the response-to-injury hypothesis of 
atherosclerosis was formulated as early as in the 1970s (Ross and Glomset, 
step in the development of atherosclerosis, but today endothelial dysfunction, 
rather than denudation, is emphasized (Ross, 1999). 
Regardless of the exact mechanism of endothelial injury, following loss of 
homeostasis in large and medium-sized muscular arteries, each characteristic 
in an artery wall; if the process is unabated and excessive it can lead to 
complicated lesions and sequelae such as myocardial ischemia. The possible 
mechanisms of endothelial dysfunction have been discussed earlier in 
density lipoprotein (LDL) concentrations, free oxygen radicals caused by 
cigarette smoking, hypertension, diabetes, genetic alterations, elevated 
homocysteine concentrations, and certain micro-organisms have been 
suggested to predispose to endothelial dysfunction (Ross, 1999). Regardless 
of the underlying mechanism or their combination, atherosclerosis is highly 
a characteristic response to endothelial dysfunction in certain arteries 
(Ross, 1993). Endothelial injury and subsequent dysfunction start a series of 
compensatory mechanisms that alter the normal homeostatic properties of 
the endothelium. First, endothelial adhesiveness with respect to leukocytes, 
mainly monocyte-derived macrophages and T-lymphocytes, and platelets and 
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its permeability increase. Furthermore, the normally anticoagulant properties 
of the endothelium become procoagulant, and vasoactive molecules, cytokines, 
to repel or neutralize the offending agents, the process keeps going and 
stimulates migration and proliferation of smooth muscle cells at the area of 
may thicken the artery wall. However, during the initial stages thickening 
is compensated by gradual dilatation of the artery wall and the diameter of 
the lumen remains unchanged (Glagov et al., 1987). Continuous cycles of 
accumulation of mononuclear cells, migration and proliferation of smooth 
advanced complicated lesion is formed. At some point, the compensatory 
mechanisms dilating the artery lumen will be lost and the lesion will obstruct 
Taking the previous observations into account, endothelial dysfunction is 
today regarded as a clinical syndrome that is independently associated with 
and predicts adverse cardiac events. One of the most important factors in 
this cascade may be the reduced NO production and impaired vasodilatation, 
characteristic of a dysfunctional endothelium. Several studies (Egashira et 
al., 1993; Motz et al., 1991; Quyyumi et al., 1992; Zeiher et al., 1995) have 
demonstrated an association between the presence of coronary microvascular 
endothelial dysfunction and symptoms of angina pectoris in individuals 
 et al. 
(1995) showed an association between impaired coronary endothelium-
dependent vasodilatation and exercise-induced myocardial perfusion 
defects in individuals without clinically relevant CAD. In addition to ischemic 
symptoms and transient myocardial ischemia, endothelial dysfunction may 
have a fundamental role in the development of acute coronary syndrome 
(ACS), including acute myocardial infarction. Plaque destabilization and 
rupture comprise a detrimental process usually leading to the most severe 
(Libby et al., 2002). Endothelial dysfunction may contribute to plaque 
destabilization in several ways. A dysfunctional endothelium is associated with 
increased oxidative stress and on the other hand, decreased NO bioavailability 
(Bonetti et al., 2003). Both of these factors together and independently 
vasoreactivity favoring local vasoconstriction decreases coronary blood 
 et 
al., 1994). Finally, endothelial dysfunction is characterized by a reduction 
of endothelial anticoagulatory potential, favoring instead a procoagulatory 
milieu (McGorisk and Treasure, 1996). This shift enhances coronary thrombus 
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In summary, endothelial dysfunction is a systemic disorder that has a 
fundamental role in the development of atherosclerosis and its complications. 
Current evidence suggests that the integrity of the endothelium depends on 
the balance of all cardiovascular risk factors and vasculoprotective effects in 
a given individual, and endothelial dysfunction can be regarded as a marker 
of an inherent risk for atherosclerosis. In line with this hypothesis, the 
presence of endothelial dysfunction in either coronary or peripheral vessels 
has been shown to be an independent predictor for adverse cardiovascular 
outcomes providing prognostic information additional to that derived from 
conventional risk factor assessment (Frank  et al., 1990).  
Compared with an nonoperative setting, the role of endothelial dysfunction 
is much less investigated in perioperative cardiac morbidity. Major surgery 
predisposes to several factors that may damage the endothelium, including 
tissue injury, blood volume loss, and, on the other hand, hypervolemia due 
myocardial ischemia and infarction, many of the risk factors for perioperative 
endothelial injury are congruent with those for perioperative cardiac 
complications. As discussed earlier, the current knowledge on pathophysiology 
of perioperative myocardial ischemia and infarction is mainly theoretical and 
based on diverse observations. Furthermore, the pathophysiology of PMI 
likely differs to some extent from that of nonoperative MI and the majority of 
perioperative MIs are of type 2 (Biccard and Rodseth, 2010). Findings from 
several animal models (Kurzelewski et al., 2005; Mulivor and Lipowsky, 2004; 
Platts et al., 2003; Wang et al., 2005) and one observational study including 
aortic surgery patients (Rehm et al., 2007) indicate that endothelial glycocalyx 
sheds during ischemia-reperfusion and major surgery, and this seems to be a 
endothelial injury is known to impairs vasodilatation, contributes to enhanced 
plaque vulnerability and possible rupture, and favors thrombus formation 
(Bonetti et al. 2003). In the light of these observations, endothelial dysfunction 
appears to be a logical contributor to the development of perioperative 
myocardial ischemia and PMI. However, currently there are only a few studies 
that have been investigated perioperative endothelial glycocalyx injury in 
humans, and its potential association with PMI is unknown.
the endothelial glycocalyx in patients undergoing surgeries for thoracic and 
abdominal aorta. The authors demonstrated a multiple rise in syndecan-1 
and heparan sulfate plasma levels after either global or regional ischemia 
followed by reperfusion. However, ICAM-1 and VCAM-1 levels remained 
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basically unchanged (Rehm et al., 2007). The association of endothelial 
injury with postoperative complications was not investigated in this study. 
In 2014 Manchurov and colleagues reported the results of a small, albeit 
interesting clinical trial of the effect of remote ischemic preconditioning 
(RIPC) on endothelial function in patients with acute MI undergoing primary 
percutaneous coronary interventions (pPCIs) (Manchurov et al., 2014). 
dilation test (Thijssen et al.
improved endothelial function and the effect remained constant up to the 
seventh day after the procedure. The improvement was speculated to be 
due to elevation of Nrf2, which may activate the genes responsible for anti-
 et al., 2013; 
Purdom-Dickinson et al., 2007). Despite the improved endothelial function in 
the RIPC group, the results of PCI as well as post-procedural cardiac functions 
were comparable between the two groups (Manchurov et al., 2014). No other 
outcome measures were investigated in this study. Another study investigating 
endothelial injury in patients with acute MI undergoing PCI was published 
in 2013 by Ostrowski and colleagues (Ostrowski et al., 2013). The authors 
investigated the potential association between sympathoadrenal activation 
and endothelial injury and the effect of these on adverse long-term outcomes 
(all-cause mortality, cardiovascular mortality, re-myocardial infarction, and 
heart failure requiring hospitalization). Endothelial injury was assessed with 
a single measurement of soluble thrombomodulin (sTM) and syndecan-1 at 
the beginning of pPCI. The results indicated that sympathoadrenal activation, 
and syndecan-1 were associated with heart failure and mortality (Ostrowski 
et al., 2013). 
The data on endothelial dysfunction after (surgical) procedures and its 
association with adverse outcomes is scarce and rather low in quality. The 
markers and methods used to demonstrate endothelial injury vary largely 
in atherosclerotic coronary arteries in 1986 by Ludmer and colleagues 
(Ludmer et al., 1986), invasive assessment of coronary endothelial function 
along with graded intracoronary infusions of endothelium-dependent 
vasodilators could be considered the “gold standard” for testing of endothelial 
function (Hasdai and Lerman, 1999). Since 1990s, however, less invasive or 
noninvasive techniques have been developed. These include strain gauge 
forearm plethysmography in conjunction with intra-arterial infusion of 
mediated endothelium-dependent dilatation (FMD) of the brachial artery 
during reactive hyperemia. The techniques are based on the understanding 
that endothelial dysfunction is not restricted to the coronary arteries, but is 
a systemic disorder that affects also peripheral vasculature. Indeed, FMD has 
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been shown to correlate with coronary dilatation by two studies (Anderson 
et al., 1995; Takase et al., 1998). However, despite efforts to standardize 
the use of FMD (Corretti et al., 2002), protocols still vary among different 
laboratories and are investigator-dependent (Corretti et al., 2002; Anderson, 
1999 ). Recent clinical studies have commonly used plasma levels of circulating 
endothelial glycocalyx components to detect endothelial injury (Rehm et 
al., 2007; Ostrowski et al., 2013; Bro-Jeppesen et al., 2016; Johansen et al., 
2015; Ostrowski et al., 2015). Although it can be demonstrated that some 
of these components originate from the coronary glycocalyx, (Rehm et al., 
2007), no study has shown in humans that detection of endothelial glycocalyx 
markers in peripheral circulation correlates with coronary endothelial injury. 
Furthermore, the superiority of any marker in demonstrating endothelial 
injury in clinical setting has not been demonstrated.
To summarize, considering the mechanisms of endothelial glycocalyx 
injury and physiological disturbances potentially associated with major 
surgery, it is hardly surprising to detect signs of endothelial dysfunction after 
surgery. Whether this has an impact on perioperative cardiac complications 
Also unclear is whether preoperatively detected endothelial dysfunction 
whether interventions aimed at maintaining glycocalyx integrity prevent 
perioperative cardiac complications, opening the door for future studies.
ASSESSING PERIOPERATIVE CARDIAC RISK
recommended for all patients undergoing major non-cardiac surgery? 
Probably not. The risk for perioperative cardiac complications is only 1-2% in 
patients aged 40 years (Goldman, 1994) and, while not investigated, is likely 
even lower in younger patients. Instead of exposing patients to unnecessary 
are costly, we need to be able to identify the patients with increased cardiac 
The medical history and clinical examination remain applicable and 
perioperative cardiac risk. The risk is estimated to be increased in elderly 
patients with an underlying heart disease, especially if manifested by a 
recent myocardial infarction or heart failure (Goldman, 1994), in patients 
with PAD, especially if manifested by chronic limb-threatening ischemia, 
(McFalls et al., 2008), in patients with chronic kidney disease (CKD), (Mooney 
et al., 2014), or in patients with preoperatively elevated B-type natriuretic 
peptide (BNP) (Rodseth et al., 2014). Furthermore, even preoperatively 
elevated cardiac troponin levels increase the risk for postoperative mortality 
(Maile et al., 2016). International guidelines emphasize the importance of 
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determining the risk for perioperative morbidity and mortality (Kristensen et 
al., 2014; Fleisher et al., 2014). However, subjective assessment of functional 
capacity correlates poorly with validated methods, such as questionnaires 
and cardiopulmonary exercise testing, and has a poor accuracy when used 
to predict postoperative complications and mortality (Wijeysundera et al., 
2018).
surgery, several cardiac risk indices have been developed based on the 
was developed as early as in 1977 by Goldman and colleagues (Goldman 
et al., 1977), and since then other indices have followed based on either 
estimate the perioperative risk based on the patient’s preoperative condition 
Eagle and Vanzetto developed indices that combined clinical risk factors with 
dipyridamole-thallium imaging (Eagle et al., 2002) and thallium – single-
photon emission computed tomography (Vanzetto et al., 1996). The authors 
demonstrated that the combination of clinical risk factors and cardiac imaging 
cardiac risk index (see Table 2), American College of Physicians (ACP) 
published guidelines for assessing and managing perioperative cardiac risk 
(Palda and Detsky, 1997). The guidelines included two steps: First, high-risk 
factors) risk groups based on the clinical risk factors by Eagle and Vanzetto. 
Second, the type of surgery was considered. Patients with low risk could 
proceed directly to surgery. For those with intermediate risk, no further 
testing was required if the surgery was non-vascular. Patients undergoing 
vascular surgery should undergo either dipyridamole-thallium imaging 
or dobutamine stress echocardiography. Those with a negative test could 
proceed to surgery and those with a positive test were placed into high-risk 
the nature of risk: if the risk was primarily due to ischemic heart disease, 
coronary revascularization should be considered; if the risk was due to heart 
failure, valvular disease, or arrhythmia, medication should be optimized 
were initially a purely evidence-based recommendation for assessing and 
managing perioperative cardiac risk. However, today, the regularly updated 
American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines have mostly replaced the ACP guidelines in routine clinical use, 
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Table 2 summarizes the different cardiac risk indices currently available, 
most recent ones of which are available as electronic calculators. 
Table 2.



















































In contrast to other indices, the surgical Apgar score includes only 
intraoperative variables (Gawande et al., 2007). Furthermore, the surgical 
complications, but rather helps to identify the patients who warrant more 
intensive monitoring. The Revised Cardiac Risk Index (RCRI), or Lee’s index 
(Lee et al., 1999), is the most widely spread and commonly used index for 
predicting major cardiac complications today. It has some limitations, however, 
including a relatively weak ability to predict an individual patient’s absolute 
cardiac risk. Furthermore, some components of the index should be revised 
to better suit modern surgery and perioperative care (Sankar et al., 2015). 
In attempting to overcome the shortages of RCRI, new indices have been 
developed, one of which is the Gupta cardiac risk calculator (Gupta et al., 
2011). This index was developed using the American College of Surgeons’ 
National Surgical Quality Improvement Program (NSQIP) 2007’s database 
including over 200 000 patients and validated a year later with a similarly 
sized cohort. Compared with RCRI, the index has been shown to be more 
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accurate in predicting major cardiac complications (Gupta et al., 2011), 
in subspecialties of vascular surgery (Gupta et al., 2012; Gupta et al., 2013). 
However, these indices lack validation outside the United States and are 
somewhat limited by the manner in which the NSQIP registry ascertained the 
relevant outcomes, i.e. all the participating sites did not apply postoperative 
troponin surveillance (Bilimoria et al., 2013), and this has been likely led to 
Additional clinical tests might be preoperatively performed to acquire 
more accurate information about a patient’s underlying heart disease or 
functional capacity. These tests may be of most value in patients with moderate 
perioperative cardiac risk, especially considering the questionable accuracy 
of subjective assessment of functional capacity (Wijeysundera et al., 2018). 
The noninvasive tests most commonly performed today include resting 
echocardiogram, cardiac stress test, and cardiopulmonary exercise testing 
(CPET). Although all of these tests provide comprehensive information 
on the patient’s cardiopulmonary condition, evidence on whether this 
 
et al., 2013). Resting echocardiogram provides information on potentially 
prognostic ventricular systolic and diastolic function, valvular abnormalities, 
wall motion abnormalities, and pulmonary hypertension. The available 
data indicate that preoperative systolic dysfunction is associated with a 
higher risk for perioperative cardiac complications and death (Rohde et 
al.
risk prediction beyond routine clinical examination (Rohde et al., 2001). 
Furthermore, resting echocardiogram is not a proxy measure of functional 
capacity in individuals who cannot exercise, for example, because of obesity 
or arthritis (Franciosa et al., 1981). Cardiac stress testing seems to add 
with intermediate or high cardiac risk (Augoustides et al., 2013). Obviously, 
patients need to be physically able to perform the test. If cardiac stress test 
is performed, the ability to reach at least seven metabolic equivalents of 
task (METs) is indicative of low perioperative cardiac risk, whereas a failure 
to reach four METs indicates increased risk (Sgura et al., 2000). Moreover, 
in the case of cardiac stress imaging, reversible defects indicate increased 
perioperative cardiac risk, with greater extent of reversibility being associated 
with progressively increasing risk (Etchelles et al., 2002). By contrast, 
risk (Etchelles et al., 2002). CPET is an increasingly popular method for 
perioperative risk assessment (Huddart et al., 2013). The test provides an 
(Wijeysundera et al., 2018), predicts a range of perioperative complications 
such as pneumonia, respiratory failure, and infection (Sankar et al., 2015). 
CPET-derived measurements indicative of perioperative morbidity and 
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mortality include inability to exercise at all, low anaerobic threshold (<11ml/
kg/min), and low peak oxygen uptake (Wijeysundera et al., 2018; James et 
al., 2014; Raby  et al.
in larger studies that include multiple sites and heterogeneous generalizable 
cohorts. In addition to the above-mentioned methods, ischemic changes in 
ambulatory ECG monitoring have been shown to predict perioperative cardiac 
complications and mortality (Frank et al., 1990; Ganz et al., 1994; Landesberg 
et al., 1993; Raby et al., 1989). Nonetheless, this monitoring method is 
today seldom applied in perioperative risk assessment, probably due to the 
amount of resources required. Rapid developments are occurring in light 
and in some cases wireless, patient-monitoring devices, and ambulatory ECG 
monitoring, as well as monitoring of other of other vital parameters, thus, 
these monitoring methods will likely establish itself again in perioperative 
research and care.
In addition to noninvasive tests, the value of preoperative coronary 
angiography in predicting perioperative cardiac complications has been 
investigated (Hwang et al., 2015; Sheth et al., 2015). Although coronary 
angiography adds prognostic information to clinical risk assessment 
(Hwang et al., 2015; Sheth et al.., 2015), it more commonly overestimates 
the risk in patients who will not suffer a perioperative cardiac complication. 
Overestimation of the cardiac risk can have negative consequences. It can 
lead to unnecessary declining or delaying of surgery or even prophylactic 
coronary revascularization, which is not risk-free and is of uncertain value 
in the perioperative period (McFalls et al., 2004). 
There is a limited amount of resources to monitor the highest risk patients 
after surgery. Intensive monitoring and restriction of mobilization can be 
harmful to the patients who do not actually need it, and this misallocates 
the resources from the patients who genuinely are at high risk. Moreover, 
the clinical outcome. For example, a prospective study by Seth et al. (2015) 
showed that 28% of the patients who sustained PMI had only minor or no 
coronary stenoses, and, on the other hand, of the six patients with suspected 
left main stenosis who underwent a surgery, none suffered PMI (Sheth et 
al., 2015). Thus, preoperative coronary angiography is not recommended 
unless it would be performed independently of surgery (Pannell et al., 
2013). However, routine cardiology consultation and individual preoperative 
by Squizzato et al. (2020). Routine preoperative cardiology consultation 
should be considered for patients with moderate to high cardiac risk.
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PREVENTIVE STRATEGIES FOR PERIOPERATIVE CARDIAC 
COMPLICATIONS
Prevention of perioperative cardiac complications has been extensively 
recommendations regarding perioperative cardiac protection, and today’s 
preventive strategies.
In terms of perioperative medication, the results of the trials have mostly 
especially in patients with cardiovascular risk factors (et al., 2014). The 
problem is, however, that in the current practice most patients are not seen 
weeks but rather only days before surgery, and it is usually too late to start 
to and titrate new medications. Furthermore, postponing the surgery is not 
always possible.
Smoking is a well-recognized risk factor for cardiovascular morbidity. 
Cigarette smoke damages the endothelial glycocalyx, leading to a reduced 
prostacyclin production, increased platelet adhesion, and development 
of atherosclerotic lesions (Pittilo, 2000). However, the effect of smoking 
status on perioperative cardiac complications has been investigated seldom. 
In 2014, a systematic review and meta-analysis including 107 studies 
showed that preoperative smoking was associated with increased general 
postoperative morbidity, wound complications, general infections, pulmonary 
complications, neurological complications, and admission to intensive care 
unit. However, no differences emerged between smokers and non-smokers in 
postoperative mortality, cardiovascular complications, bleeding, anastomotic 
leakage, or allograft rejection (Grønkjær et al., 2014). Recently, Arinze and 
colleagues investigated the effect of the duration of perioperative smoking 
cessation in a large retrospective study of patients undergoing major elective 
vascular surgery. There were no differences between the effect of long-term 
smoking cessation, short-term smoking cessation, and current smoking on 
perioperative myocardial infarction or mortality. However, long-term smoking 
cessation was associated with fewer pulmonary complications in patients 
undergoing open abdominal aortic aneurysm repair (Arinze et al., 2019).
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Beta blockers
Despite initially promising research results (Feringa et al., 2006; London et 
al., 2013; Raby et al., 1999; Welten et al., 2007) and previous widespread 
use for cardiac protection, de novo administration of beta blockers is highly 
controversial today. A recent meta-analysis demonstrated that beta blockers 
started within a day or less before surgery decreased the incidence of PMI, 
but at a cost of higher rates of stroke and death (Wijeysundera et al., 2014). 
However, a recent retrospective study by Friedell et al. (2015) showed that 
patients with high cardiovascular risk had a lower 30-day postoperative 
mortality if receiving beta blockers. Beta blocker had no effect on the mortality 
of the patients with intermediate risk and were harmful to patients with no 
cardiovascular risk factors (Friedell et al., 2015). However, in approximately 
half of the patients, beta blockers were not started de novo, which might 
explain the results. Dose titration, as recommended in the current ACC/
AHA guidelines, may optimize beta blockade, thus decreasing the undesired 
effects, namely bradycardia and hypotension, of the treatment (Anderson 
et al., 2007; Antman et al., 2008). Furthermore, the choice of beta blocker 
likely matters. The metabolism of metoprolol succinate, used, for example, in 
the POISE trial, (Devereaux et al.
in metoprolol plasma concentrations between individual patients (Ismail 
levels might be promising in reducing perioperative myocardial ischemia 
without predisposing vital organs to hypoperfusion. One previous meta-
analysis investigated this subject ten years ago and showed that esmolol 
reduced perioperative myocardial ischemia without adverse side-effects 
(Landoni et al.
such as mortality, were not investigated, and data regarding perioperative 
intravenous beta blockade are scarce.
Currently, the European and American guidelines suggest the perioperative 
continuation of beta blockers in those patients already on medication (Class 
I, Level B). The preoperative initiation of beta blockers may be considered for 
patients with high perioperative cardiac risk undergoing high-risk surgery 
(Class IIb, Level B), however, not without preoperative titration (Class III, 
Level B) (Kristensen et al., 2014; Fleisher et al., 2014). 
Perioperatively started aspirin medication does not decrease PMI or mortality, 
even in patients with cardiovascular risk factors, but instead increases the 
risk for perioperative bleeding (Devereaux et al., 2014). 
By contrast, dabigatran at a dose of 110 mg twice daily reduced the 
composite of vascular mortality, non-fatal myocardial infarction, non-
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hemorrhagic stroke, peripheral arterial thrombosis, amputation, and 
symptomatic venous thromboembolism during the 16-month follow-up of 
in the recent MANAGE study (Devereaux et al., 2018). It is important to note, 
no differences in secondary outcome measures, i.e. all-cause mortality and 
myocardial infarction, between the dabigatran and placebo groups. Over 
half of the patients used concomitant medications, such as aspirin, statins, 
or beta blockers, during the follow-up. However, the groups did not differ 
in terms of concomitant medication use (Devereaux et al., 2018). 
antiplatelet and anticoagulant treatment are patients with PAD. Recently, 
thrombin inhibition with a low-dose factor Xa inhibitor added to antiplatelet 
events and mortality in patients with systemic atherosclerosis. The COMPASS 
study showed that low-dose rivaroxaban (2.5 mg twice daily) combined with 
outcome of stroke, cardiovascular death, and myocardial infarction in patients 
with peripheral artery disease and stable CAD. Furthermore, dual pathway 
inhibition reduced major adverse limb events by 46% (Eikelboom et al., 2017; 
Steffel et al.
subgroup of patients with PAD at the highest risk of cardiovascular events. The 
dose rivaroxaban used together with aspirin in patients with PAD undergoing 
lower extremity revascularization. The results of this large, double-blind 
randomized controlled trial demonstrated that dual pathway inhibition 
major amputation of vascular etiology, MI, stroke, and cardiovascular death, 
compared with aspirin alone. Kaplan-Meier event estimates demonstrated the 
 
et al.
lower extremity revascularization appeared to be mainly due to a reduction 
in acute limb ischemia, treatment reduced hospitalization for coronary 
or peripheral thrombotic events as well. There were no differences in all-
cause mortality between the two groups. In both the COMPASS study and 
the VOYAGER PAD study, patients with dual pathway inhibition had more 
bleeding than patients with aspirin monotherapy. In the COMPASS study, 
rivaroxaban. In the VOYAGER PAD study, major bleeding rates were 2.65% 
with rivaroxaban-aspirin combination and 1.87% with aspirin monotherapy 
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rates between the groups. Whether antiplatelets or anticoagulants become 
a routine management of perioperative cardiac complications depends on 
future studies and analyses. 
Currently, the ACC/AHA guidelines state that continuation of aspirin in the 
case of nonurgent, non-cardiac surgery may be reasonable in patients without 
prior coronary stenting if the risk for perioperative cardiac complications 
outweighs the risk for bleeding (Class IIb, Level B) (Fleisher et al., 2014). 
In the case of patients with recent coronary stenting undergoing urgent 
surgery, antiplatelets should be continued, and if not possible, restarted as 
soon as possible after the surgery (Class I, Level C) (Fleisher et al., 2014).
activation and myocardial stress and its effect on cardiac protection was 
investigated in the POISE-2 trial (Devereaux et al., 2014). Clonidine did 
for perioperative cardiac protection by either European or American 
guidelines (Class III, Level B) (Kristensen et al., 2014; Fleisher et al., 2014). 
The safety of prescribing angiotensin-converting enzyme inhibitors (ACEIs) 
and angiotensin receptor blockers (ARBs) on the day of surgery is unclear. 
Only few studies have investigated the effect of continuation or discontinuation 
of ACEIs and ARBs on the day of surgery, with the result that continuing 
renin-angiotensin system inhibition increased the risk of intraoperative 
hypotension (Rosenman et al., 2008; Turan et al., 2012; Roshanov et al., 2017) 
and potentially increased the risk of MINS, stroke, and mortality at 30 days 
(Roshanov et al., 2017). The (ESC/ESA) guidelines recommend considering 
temporary discontinuation of ACIs and ARBs prior to surgery when prescribed 
for hypertension, but recommend continuation in stable patients with 
heart failure or left ventricular dysfunction (Class IIa, Level C) (Kristensen 
et al., 2014). The ACC/AHA guidelines indicate that ACI and ARB therapy 
should be continued over the perioperative period (Class IIa, Level B), and 
if the agents are discontinued, they should be restarted as soon as possible 
after the surgery (Class IIa, Level C) (Fleisher et al., 2014). Data regarding 
perioperative calcium channel blockers are scarce. A meta-analysis from 
2003 showed that calcium channel blockers reduced myocardial ischemia 
to diltiazem (Wijeysundera and Beattie, 2003). Generally, calcium channel 
blockers are continued over the perioperative period for patients already on 
medication. There are no recommendations regarding initiation of calcium 
channel blockers only for perioperative cardiac protection.
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In surgical patients, statins have been shown to reduce perioperative major 
cardiac complications and mortality. The effect has been shown in both 
large observational studies (Berwanger et al., 2016; Lindenauer et al., 2004; 
Suckow et al., 2015) and randomized trials (Durazzo et al., 2004; Xia et al., 
2015). In the recent observational study of the VISION cohort, perioperative 
30-day mortality, MINS, and stroke (Berwanger et al., 2016). The ACC/AHA 
guidelines recommend perioperative continuation of statin use (Class I, Level 
B). Initiation of statin therapy may be reasonable in patients undergoing 
vascular surgery (Class IIa, Level B) as well as in patients undergoing other 
high-risk surgeries with cardiovascular risk factors (Class IIb, Level C) 
(Fleisher et al., 2014). However, the (ESC/ESA) guidelines suggest that for 
statin-naïve patients the treatment should be started two weeks before 
surgery (Kristensen et al., 2014).
Preoperative coronary revascularization does not improve long-term survival 
or prevent PMI or in-hospital death in patients with stable coronary artery 
disease (McFalls et al., 2004). Thus, coronary revascularization should not be 
preoperatively performed, unless indicated independently of surgery (Class 
I, Level C) (Fleisher et al., 2014). Regarding patients with recent coronary 
revascularization procedures, elective non-cardiac surgery should be delayed 
at least 14 days after balloon angioplasty, 30 days after implementation of 
bare-metal stent (BMS), and ideally 365 days after implementation of drug-
eluting stent (DES) (Class I, Levels C and B) (Fleisher et al., 2014). 
Early coronary angiography after MINS was investigated in a recent 
observational study by Rostagno et al. (2019). The major limitation of the 
study was the small number of patients (only 20% of 92 patients with MINS 
underwent coronary angiography) and the selection bias; however, the 
study showed that early coronary revascularization might improve long-
term survival after MINS (Rostagno et al., 2019). Parashar et al. (2016) 
PMI patients admitted to coronary angiography with a focus on pPCI. The 
study did not compare the survival of PMI patients who did and did not 
undergo the procedure; however, the authors demonstrated that bleeding 
after PCI predicted both short- and long-term mortality. Other predictors 
were peak troponin level and PAD for short-term mortality and older age, 
vascular surgery, and renal dysfunction for long-term mortality (Parashar 
et al., 2016).
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Although volatile anesthetics have cardioprotective effects (Pagel, 2013), the 
use of volatile anesthetics has not reduced myocardial ischemia, major cardiac 
complications, troponin, or BNP concentrations in major non-cardiac surgery 
(Lindholm et al., 2013; Lurati Buse et al., 2012). Furthermore, as recently 
demonstrated by Landoni et al. (2019) and colleagues, volatile anesthetics 
do not reduce mortality among patients undergoing elective coronary artery 
support (Lindholm et al.
or spinal) anesthesia over general anesthesia have been highly debated in the 
literature. Studies, including randomized controlled trials and a meta-analysis, 
have shown some evidence of improved outcome and reduced postoperative 
morbidity with regional anesthesia (Bode et al., 1996; Mauermann et al. 2006; 
Rigg et al., 2002).A more recent retrospective analysis of nearly 400 000 
reduction in postoperative morbidity and mortality in patients receiving 
neuraxial anesthesia (Memtsoudis et al., 2013). Currently, there are no studies 
investigating the effect of general versus neuraxial anesthesia targeting 
this effect in patients undergoing lower extremity revascularization – a 
subgroup of surgical patients at high risk of perioperative cardiac events. 
No differences were observed in mortality, myocardial infarction, or lower 
limb amputation between patients receiving neuraxial anesthesia and 
general anesthesia. Nevertheless, neuraxial anesthesia was associated with 
 et al. 2013). 
Neuraxial anesthesia may be considered in patients with cardiac risk factors 
who do not have contraindications, such as antiplatelet or anticoagulant 
Level B) (Kristensen et al., 2014).
Blood loss and anemia are associated with impaired oxygen delivery 
to the tissues. Considering this, more liberal red blood cell transfusion 
cardiac complications and mortality. However, higher transfusion thresholds 
have not been shown to affect short- or long-term mortality in large trials 
(Carson et al., 2011; Carson et al., 2015). Regarding perioperative morbidity, 
liberal transfusion thresholds may indeed reduce myocardial infarction, but 
tend to increase other complications such as infections (Brunskill et al., 2015). 
Overall, data regarding perioperative red blood cell transfusion thresholds 
for perioperative cardiac protection are limited, and no recommendations 
for optimal hemoglobin level exist. It is also possible that different patient 
by Möller and colleagues suggested potential harm for patients undergoing 
major vascular surgery with restrictive transfusion thresholds (Möller et al., 
2019). Currently, further trials comparing liberal versus restrictive transfusion 
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thresholds are underway, and results can be expected in becoming years.
between intraoperative hypotension and mortality has been demonstrated in 
several observational studies (Abbott et al., 2018; Monk et al., 2015; Roshanov 
et al., 2019; van Waes et al., 2016; Walsh et al., 2013). Furthermore, even 
short periods of intraoperative hypotension are associated with myocardial 
injury (Abbott et al., 2018; Roshanov et al., 2019; Walsh et al., 2013). 
Recently, Roshanov and colleagues investigated the potential interaction 
between existing coronary artery disease and perioperative hypotension 
and demonstrated that perioperative hypotension is associated with 30-
day myocardial infarction and cardiovascular mortality independently 
of the degree of CAD on perioperative coronary angiography (Roshanov 
et al., 2019). Another recent study by Abbot and colleagues expanded 
on the current knowledge regarding perioperative hemodynamics and 
cardiac complications by demonstrating that in addition to intraoperative 
hypotension, also intraoperative tachycardia is associated with myocardial 
injury, myocardial infarction, and mortality (Abbott et al., 2018).
Severe postoperative pain is reported in 5-10% of surgical patients. 
This increases sympathetic drive and delays recovery (Liu and Wu, 2007; 
White and Kehlet, 2007). Sympathetic activation increases myocardial 
oxygen consumption and may precipitate myocardial ischemia, especially 
management of postoperative pain is essential. A meta-analysis published in 
2013 compared the effects of epidural analgesia and systemic analgesia and 
showed that epidural analgesia was associated with a decrease in mortality, 
supraventricular tachyarrhythmias, deep-vein thrombosis, respiratory 
problems and pneumonia, and postoperative nausea, vomiting, and ileus 
(Pöpping et al., 2013). Furthermore, in recent years, ultrasound-guided 
regional anesthetic techniques have developed, and especially different fascial 
plane blocks have become popular in truncal analgesia. These techniques 
provide a feasible alternative to thoracic epidural, for example, in patients 
with coagulation abnormalities and at increased risk of epidural hematoma. 
There is moderate evidence that fascial plane blocks and epidural analgesia 
are equally effective in treating postoperative pain, while fascial plane blocks 
are associated with fewer episodes of hypotension (Khalil et al., 2017; 
Baeriswyl et al., 2018). However, further investigation is needed to determine 
perioperative cardiac complications, more frequent or continuous monitoring 
of vital signs and parameters has been proposed. A large meta-analysis by 
Maharaj and colleagues demonstrated that rapid response systems (RRS) are 
able to reduce in-hospital mortality and cardiopulmonary arrests, despite 
varying practices in vital sign monitoring and alarm activation (Maharaj et al., 
2015). However, opposing results have been presented as well (Chan et al., 
2010). Despite the compelling logic of frequent monitoring and timely delivery 
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of interventions, high-quality data showing an improvement in clinically 
at best. Furthermore, currently there are no high-quality studies focusing 
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AIMS OF THE STUDY
The purpose of this study was to investigate the incidence and prognosis of 
PMI in an unselected cohort of patients undergoing non-cardiac surgery in 
a Finnish tertiary care hospital and to evaluate how the Gupta cardiac risk 
calculator performs in predicting major perioperative cardiac complications 
outside the United States. Furthermore, this study aimed to examine the 
of silent postoperative ischemia and perioperative glycocalyx injury. Finally, 
considering the pathophysiological mechanisms of PMI and hemodynamic 
factors affecting the development of perioperative myocardial ischemia, this 
perioperative cardiac protection.
1. To investigate the incidence, prognosis and risk factors of PMI 
in an unselected cohort of patients undergoing non-cardiac 
surgery in a Finnish tertiary care hospital and to determine how 
the Gupta cardiac risk calculator performs in predicting major 
perioperative cardiac complications outside the United States (I).
2. 
postoperative myocardial ischemia in patients with high 
perioperative cardiac risk (II).
3. To examine the potential association of endothelial glycocalyx 
4. To determine whether intravenous esmolol, titrated according 
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MATERIAL AND METHODS
This thesis comprises four different studies. Studies I-III are prospective 
observational studies, including adult non-cardiac surgery patients with 
systematic perioperative ischemia screening. Study IV is a systematic review 
esmolol in preventing perioperative cardiac complications.
The results of Studies I-III are reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) guidelines 
for observational studies (von Elm et al.
developed to improve the reporting of results of observational studies. The 
guidelines aims to add transparency to observational studies and to enable 
critical assessment of the results by others. Furthermore, transparent reporting 
is needed to determine whether and how the results of an observational 
study can be included in systematic reviews. The STROBE guidelines consist 
of a 22-item check list that is presented in Appendix 1. The items cover the 
article’s title and abstract (1), introduction (2-3), methods (4-12), results 
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Table 3 summarizes the patient cohorts and recruitment times of Studies I-III. 
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Considering the reported incidence of PMI in the earlier studies and in 
to recruit 500 consecutive patients in Study I. To ensure representativeness 
of the cohort, an amendment was applied to analyze the routine clinical data 
of the eligible patients whose consent was missing, mainly due to challenges 
during off-hour urgent operations. The recruitment took place between April 
and June 2014. All consecutive patients aged 50 years or older undergoing 
non-cardiac, non-organ transplantation surgery were considered eligible 
for the study. 
The selection process of the studies for the systematic review and meta-
analysis (Study IV) is presented in Figure 4.
Figure 4.
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In Study II, the aim was recruit patients at heightened risk for perioperative 
cardiac complications. The recruitment took place between March and July 
2015. Patients aged 65 years or older undergoing vascular surgery were 
deemed eligible for the study. Both elective and urgent/emergency operations 
The following patients were prospectively excluded: (1) those scheduled 
for a re-operation during the same hospitalization, (2) those assigned 
for treatment in the ICU after surgery, (3) those whose preoperative ECG 
included conduction defect precluding ST-segment analysis, and (4) those 
on digitalis medication. 
investigate the potential association of endothelial glycocalyx injury with PMI. 
The patients included in Study I were investigated. All the PMI patients of the 
primary cohort with a complete series of follow-up blood samples (n=15) 
and four propensity-matched controls for each PMI patient (n=60) were 
included in the analysis. The variables used for matching were age, gender, 
main medical history, ongoing medications, and intraoperative data. Of note, 
of the 27 PMI patients in Study I, 12 patients had to be excluded because 
of the missing blood samples. Previous randomized trials and systematic 
reviews have demonstrated that although perioperatively started beta 
blockers reduce myocardial ischemia and infarctions the risk for all-cause 
mortality increases mainly due to complications caused by bradycardia and 
hypotension (Devereaux et al., 2008; Le Manach et al., 2012; Mostafaife et 
al., 2015; Blessberger et al., 2018). However, in the majority of those studies, 
patients were treated with oral high-dose beta blockade that was started 
without titration of the dose. Data regarding individually adjusted beta 
blockade are very limited. Accordingly, Study IV was conducted. Esmolol 
was chosen because of the rapid onset of action, short half-life, and cardio-
serious complications.
The literature search covered three major databases, PubMed, Ovid 
Medline, and the Cochrane Central Register for Controlled trials. The last 
search of the databases was performed on 2 May 2017. No restrictions were 
applied regarding the publication date or language. The search strategy is 
presented in Appendix 2. In addition to electronic search, the reference lists 
of relevant articles were hand-searched for potentially relevant studies. The 
study selection consisted of two phases: First, two authors (A.O. and L.V.) 
reports considered as potentially pertinent by at least one of the assessors 
were retrieved as complete articles. Second, A.O. and L.V. independently 
assessed the retrieved complete articles and selected relevant ones for the 
the last author (E.W.) was consulted. The selection criteria are presented 
in Appendix 3. Database searches yielded a total of 249 reports, published 
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between 1973 and 2017, of which 56 full texts were reviewed. Ten additional 
After reviewing the total of 66 full texts, 52 reports were further excluded, 
remaining 14 studies, 11 reported only intraoperative outcomes and are 
summarized in Appendix 4. Finally, three reports presenting original data 
patients between 1997 and 2000 and were published in 1998 to 2000.
METHODS
The ethics committee of the Department of Surgery in Helsinki University 
Hospital provided ethics approval for all of the prospective observational 
studies (I-III) before starting the recruitment of patients. Studies I-III were 
conducted in Meilahti Hospital, Helsinki, Finland. The hospital is a tertiary 
care university hospital providing round-the-clock surgical care in the 
disciplines of abdominal, vascular, cardiac, and thoracic surgery. Written 
informed consent was obtained before study inclusion from all the patients 
or their next-of-kin in Studies I-III. Patients were informed that they could 
at any time withdraw their consent without explanation.
In Studies I-III, every patient’s perioperative cardiac risk was evaluated 
using the Gupta cardiac risk calculator (Gupta et al., 2011). Development, 
validation, and the main principles of this model are explained in detail in 
the review of literature. The evaluation was done in retrospect, thus having 
no impact on monitoring or treatment decisions.
In Study I, blood samples for high-sensitive cardiac troponin T (electro-
chemiluminescence immunoassay (ECLIA); Roche Diagnostics International 
and third postoperative mornings. Furthermore, together with TnT, 5 mL of 
EDTA plasma was taken for future analysis of EG markers and IL-6. In Study II, 
the same laboratory tests were conducted four times perioperatively: before 
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studies, additional cardiac biomarkers and ECGs could be ordered at the 
treating physicians’ discretions. In Study III, the blood samples and ECGs of 
Study I were used. Blood samples taken preoperatively and at six hours, and 
24 hours postoperatively were analyzed for TnT, EG markers and IL-6. TnT 
levels were determined immediately after sampling from the vein or arterial 
line, while plasma for EG markers and IL-6 was centrifuged at 22°C at 3170 
rpm for 10 min and stored at -80°C until analysis. Biomarkers of EG injury 
6) were analyzed at the Minerva Foundation Institute for Medical Research, 
Helsinki, Finland, by commercially available immunoassays according to the 
manufacturer’s recommendations: sTM (Quantikine™ ELISA, R&D Systems 
Europe, Ltd., Abingdon, UK; the mean minimum detectable dose (MDD) 
and 5.7-8.0%); syndecan-1 (Human sCD138 (Syndecan-1) ELISA Kit, Nordic 
BioSite AB, Täby, Sweden; the mean MDD 4.94 ng/mL, intra- and inter-assay 
CV 6.2% and 10.2%); VAP-1 (Quantikine™ ELISA, R&D Systems Europe, 
Ltd., Abingdon, UK; the mean MDD 0.024 ng/mL, intra- and inter-assay CV 
1.5-2.4% and 4.5-4.8%); IL-6 (Quantikine™ ELISA, R&D Systems Europe, 
Ltd. Abingdon, UK; the mean MDD < 0.70 pg/mL, intra- and inter-assay CV 
1.6-4.2% and 3.3-6.4%).
In addition to daily ECG recordings, all patients in Study II were 
postoperatively monitored with a continuous ECG (Holter) recorder (SEER 
12; Getemed, Teltow, Germany) to detect possible postoperative ischemia, 
and with a 3-axis accelerometer (Faros 360° eMotion; Mega Electronics 
Ltd., Kuopio, Finland) to enhance ischemia detection by distinguishing the 
ST-segment deviations caused by postural changes from the true ones. The 
monitoring was started immediately after arriving to the postanesthesia 
care unit (PACU) after surgery and continued for the next 72 hours or until 
discharge. The Holter monitoring stored data at one-minute intervals. 
Bipolar leads I, II, and III and unipolar leads aVL, aVR, aVF, and V1-V6 were 
used for Holter recording. The recordings were analyzed using an EK-Pro 
analysis program (GE Healthcare, Little Chalfont, UK), which stores data on 
patient’s normal QRS-complexes and ST-segments (the calculated average 
during stable period) and marks abnormal ones relative to the baseline. The 
accelerometer continuously collected data on whether a patient was in an 
upright or supine position, lying on either side, or moving. The detection was 
based on the device’s three sensitive axes that measure static (acceleration 
due to gravity) and dynamic (acceleration due to movement of the device) 
acceleration.
In Studies I and III, information about potential ischemic signs and 
symptoms was prospectively collected from electronic medical records, daily 
symptoms (chest pain, neck, jaw or arm discomfort, dyspnea, arrhythmias, 
or nausea) that were recorded.
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The study group did not interfere with the perioperative treatment of the 
patients. However, a cardiologist (J.V.) formulated a local recommendation 
on PMI management based on national guidelines (Niemelä et al., 2014) and 
the document was distributed to all physicians involved in the treatment of 
surgical patients.
Data sources
In Studies I-III, patients’ demographic and medical baseline characteristics 
and current clinical data were obtained from electronic medical records 
(Uranus 8.4.3; CGI Group, Montreal, Quebec, Canada and Caresuite 8.2; 
form (eCRF) created for the study. Mortality dates were retrieved from the 
by reviewing the postoperative medical records.
In Study IV, the following data were extracted from the selected studies: 
1.) the number of patients randomized to receive esmolol and their baseline 
demographic and clinical characteristics; 2.) the exclusion criteria of each 
study and information about dropouts and withdrawals; 3.) timing and 
duration of the intervention, bolus, or infusion type of administration, the 
dosage of the intervention drug, and potential unplanned co-interventions; 
4.) the number of patients randomized into the no-esmolol group and their 
baseline demographic and clinical characteristics. To cover the existing 
literature and current options for treatment as comprehensively as possible, 
no restrictions regarding the potential treatment of the control group were 
applied. Instead, placebo, standard treatment, or treatment with oral beta 
blockers or with any other medication started for perioperative cardiac 
protection was considered as a comparator. 
Outcome measures
In Study I, the primary outcomes were PMI and 90-day mortality. The 
secondary outcome was the performance of the Gupta cardiac risk calculator. 
In Study II, the primary outcomes were PMI and cumulative ischemic load 
deviation and ischemic time). The primary outcome of Study III was the 
magnitude of perioperative endothelial glycocalyx injury and its association 
with PMI. The primary outcomes of Study IV were 30-day major cardiac 
ischaemia, cardiac arrest, cardiac death, heart failure, unstable angina pectoris 
(UAP), new-onset arrhythmias, acute kidney injury (AKI), composite of 
renal events (AKI, need for renal replacement therapy (RRT), or worsening/
development of chronic kidney failure), and composite of cardiac events (MI, 
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UAP, heart failure, new-onset arrhythmias, or cardiac death). The secondary 
as a heart rate below 60 bpm or decreased heart rate together with clinical 
features suggestive of hypoperfusion and a blood pressure level requiring 
vasoactive medications), bronchospasm, stroke, neurologic sequelae, serious 
infection/sepsis, and all-cause mortality. Based on preliminary searches, a 
small number of eligible studies was expected, and thus, additional studies 
meta-analysis. Appendix 4 presents the characteristics of the studies with 
only intraoperative follow-up data.
In Studies I-III, the diagnosis of PMI was based on patients’ baseline TnT level, 
repeated TnT measurements, ECGs, and ischemic signs or symptoms which 
dyspnea), 2) cardiac imaging evidence of myocardial infarction, and 3) autopsy 
of the patients with at least one TnT value above the upper reference limit 
(14 ng/L) and did the PMI diagnoses. The diagnoses were set according to 
the following criteria: 1) a rise and/or a fall of TnT with at least one value 
above 14 ng/L and 2) new ECG changes indicative to myocardial ischemia 
segment depressions in two contiguous leads, T-inversions in two contiguous 
leads, and new left bundle branch block) and/or 3) other ischemic features.
In Study II, the analysis of ischemia was based on the magnitude of ST-
segment deviation, measured at either 60 or 80ms after the J-point depending 
for at least one minute, as suggested by Jernberg and colleagues (Jernberg 
et al., 2002). The data obtained from the accelerometer was manually 
combined with the Holter data, and the patient’s position was considered 
in the ischemia diagnostics. J.V. analyzed all the Holter recordings including 
ischemic events and excluding artifacts and false-positive events. If ischemia 
occurred only in one lead, the patient’s preoperative ECG was revised. If the 
postoperative deviation was not considered ischemia. If the preoperative 
ST-segment deviation was 0-1 mm in magnitude, this was subtracted from 
the postoperative deviation to obtain the accurate change.
60
To assess the completeness of extracted data, a data completeness score based 
on 36 data items was calculated. The methodology of the scoring system 
and the data completeness scores of the included studies are presented in 
Appendix 5. In addition to the completeness of data, the quality of data was 
assessed using the GRADE approach (Guyatt et al., 2008). GRADE includes the 
following domains: risk of bias, presence of reporting bias, inconsistency of 
data (heterogeneity), indirectness of data (was the outcome of interest tested 
in a population of interest for the intervention of interest), and imprecision of 
data (is the sample size smaller than optimal information size and/or is the 
CI wide, covering zones of no effect (RR 1.0), potential harm (RR 1.25), and 
The risk of bias of the selected studies was assessed using the Cochrane tool 
(Higgins et al., 2011) to ascertain the risk of bias of randomized trials. The 
following domains are taken into consideration in assessing the risk of bias: 
adequate random sequence generation, adequate allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, 
reporting of attritions or exclusions and re-inclusions, and selective outcome 
reporting. To further investigate the relevance of the results and the strength 
of evidence of the meta-analysis, trial sequential analysis (TSA) was conducted. 
TSA helps to apprehend if the detected effect holds, based on the cumulative 
evidence and to determine how many participants are needed to acquire 
the optimal information size.
The statistical analyses were performed using SPSS versions 22 and 23 
(SPSS; Chicago, IL, USA) (I-III) and Review Manager (RevMan) version 5.3 
(Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014) (IV).
continuous variables with Mann-Whitney U-test (I-II, III) or Student’s t-test 
(II), as appropriate. Data are presented as absolute numbers (percentage 
without PMI was investigated with Kaplan-Meier analysis, and the survivals 
were compared using Mantel-Cox log rank test (I). The predictive abilities 
of the Gupta cardiac risk calculator (I), ischemic load (II), and endothelial 
glycocalyx markers and interleukin-6 were tested by calculating areas 
under receiver operating characteristic curves (AUCs) with 95% CIs. The 
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negative (LR-) likelihood ratios. To compare perioperative glycocalyx injury 
in patients with and without PMI (III), four propensity-matched controls 
for each PMI patient were selected. A propensity score was calculated for 
each patient based on demographic and medical data. Variables included 
these variables includ age, gender, main medical history, medications, and 
intraoperative data.  
To assess the magnitude of differences between PMI and non-PMI patients’ 
preoperative and 6- and 24-hour postoperative values and the highest values 
of EG markers and IL-6, Hodges-Lehman estimators with 95% CIs were 
calculated (III). In the meta-analysis (IV) an individual patient was used as 
the unit of analysis and the analysis was based on intention-to-treat data 
from the individual studies. 
Risk ratios (RRs) were calculated as summary measures. Heterogeneity 
across the individual studies was determined by calculating I2 statistics, 
which was interpreted according to the following guidelines: 0-40% may 
not be important, 30-60% may present moderate heterogeneity, 50-90% 
represents substantial heterogeneity, and 75-100% represents considerable 
heterogeneity (Higgins et al., 2013). Fixed effect or random effects modelling 
was used for analysis, as appropriate. The random effects model was applied 
reported in forest plots with 95% CIs. A two-sided p-value of < 0.05 was 
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RESULTS
FINNISH TERTIARY CARE HOSPITAL 
At the time of enrollment, 570 eligible patients underwent a non-cardiac 
surgery. Altogether 385 patients (67.5% of the all the eligible) consented 
to participate in the study and formed the cohort with systematic ischemia 
screening. Of these patients, 172 underwent vascular, 80 thoracic, and 133 
gastrointestinal surgery. Ten patients (1.8% of the all the eligible) declined 
to participate and were excluded from the study. The 175 patients who could 
not consent or whose consent could not be ascertained formed the cohort 
with routine perioperative care. 
A perioperative TnT release > 14 ng/l was observed in 75 patients (19.5%) and 
27 patients (7%) sustained PMI, all of which of the ST-segment depression-
type. The incidence of PMI was highest in vascular surgery patients: 19 of 
172 (11%) versus 8 of 133 (6%) and 0 of 80 (0%) in gastrointestinal and 
thoracic surgery patients, respectively (p<0.01). 
Table 4 presents the clinical characteristics of the patients with and without 
PMI. Patients who sustained PMI had more pre-existing cardiovascular 
morbidity, higher ASA class, lower nadir hemoglobin (Hb) during 
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Notably, 182 (47.3%) of the patients had a preoperatively elevated TnT. 
sustained PMI (p< 0.01). The majority of PMIs (16 of 27, 59.3%) occurred 
sustained PMI had symptoms of myocardial ischemia. Four patients underwent 
a coronary angiography after the diagnosis of PMI and for three of them a 
coronary revascularization was performed. Cardiovascular medication was 
optimized in four patients. In the remaining 19 patients, the diagnosis of 
PMI did not lead to any interventions.
The 90-day mortality was 7.3% among all the patients. The mortality 
who did not, 29.6% versus 5.6%, (p< 0.01). Of the deaths in PMI patients, 
non-PMI patients were distributed evenly over the entire 90-day period. Six 
(75%) of the eight deaths in PMI patients had a vascular cause. The 90-day 
mortality of the patients with a perioperative troponin release, but without 
other ischemic signs or symptoms was 10.4%.
The Gupta cardiac risk calculator predicted PMI with an AUC of 0.73 (95% 
0.84), respectively. In addition, the performance of the cardiac risk index in 
predicting 90-day mortality was tested. The index predicted 90-day mortality 
with an AUC of 0.75 (95% CI: 0.66-0.85). The best cut-off value was 1.85 with 
and 0.38 (95% CI: 0.21-0.68), respectively.
The patients whose consent was missing did not differ from the cohort with 
systematic ischemia screening in terms of baseline characteristics. However, 
urgent/emergency surgeries. The distribution of the types of surgeries was 
similar in both cohorts.
TnT measurements were ordered at treating physicians’ discretion in 
39 (22.3%) of the 175 patients. Three patients (1.7%) sustained PMI. The 







































SILENT POSTOPERATIVE ISCHEMIA IN PATIENTS WITH HIGH 
PERIOPERATIVE CARDIAC RISK
Ninety patients meeting inclusion criteria underwent a vascular surgery 
during enrollment. Thirty-three patients (36.7%) were not enrolled in 
the study for the following reasons: 2 did not consent, 12 had pre-existing 
conduction defects precluding the ST-segment analysis, and 19 could not be 
enrolled due to logistic reasons. As the continuous ECG (cECG) recordings were 
reviewed, six additional patients had to be excluded because of unreadable 
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The total time of monitoring was 64.0±20.2 hours per patient. Seventeen 
patients (33.3%) had ischemic episodes, 11.9±32.9 episodes per patient, 
range 0 to 184, all of which were of ST-segment depression type. The details 
of postoperative ischemia in patients with and without PMI are summarized 
in Table 6. 
Most of the ischemic episodes occurred during the second postoperative 
day. Only 17.6% of the postoperative ischemia associated with ischemic 
symptoms. The mean heart rate during non-ischemic stages of monitoring 
was higher in patients with postoperative ischemia than in patients without 
postoperative ischemia (90.9±17.6 beats per minute (bpm) versus 71.7±12.1 
bpm, p<0.001). Ischemic episodes were preceded by an increase in heart 
emerged in the pre-ischemic changes of the heart rate in patients with and 
without PMI.
PMI
Five patients (9.8%) sustained PMI. All the PMIs were diagnosed during 
pectoris. The cumulative ischemia duration, the duration of the longest 






















who sustained PMI than in those who did not (Table 6). IL predicted PMI 
with an AUC of 0.87 (95% CI: 0.75-0.99). The best cut-off value was 12.5 
2.36-6.23), and 0.0, respectively. 













The sensitivities of the cECG leads and their combinations in detecting 
postoperative ischemia are shown in Table 8. 
Lead V4 outperformed V5 in ischemia detection sensitivity. At the beginning 
of ischemia, the best detection sensitivity (97.2%) was acquired by combining 
the leads V4, V5, II, and aVF.
The data recorded by the accelerometer were used to classify the following 
seven postures: supine, prone, on the right and left side, standing/sitting, 
half-sitting, and moving. The correlation between posture and simultaneous 
ST-segment deviation was analyzed in individual patients and in the whole 
cohort. Additionally, the ischemic alarms to which a change in the posture 
could be associated were studied. There was not a clear correlation between 
postures and ST-segment deviation either in individual patients or in the 
whole cohort. However, patients did not cycle through all the postures, and 
thus, the postural variable was distributed unequally. Six ischemic alarms 
associated with a turn from back to side were observed. Combining the cECG 
and accelerometer data suggested that all of the alarms were true positives, 
no movement artifacts were found.
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ASSOCIATION OF ENDOTHELIAL INJURY AND SYSTEMIC 
INFLAMMATION WITH PERIOPERATIVE MYOCARDIAL 
INFARCTION
were included in the study. To assess the generalizability of the results, the 
baseline characteristics of the primary study patients with all plasma samples 
taken were compared with the baseline characteristics of those with lacking 
plasma samples. Except for differences in the number of urgent/emergency 
surgeries, vasopressor support, ASA class, and perioperative cardiac risk, 
patients were comparable in terms of baseline characteristics (Appendix 6).
PMI
The 90-day mortality of PMI patients was 20%, compared with 8.3% in 
non-PMI patients. The median values of EG markers and IL-6 are presented 










The patients with PMI had higher IL-6 levels during the whole 24-hour 
follow-up. However, sTM, syndecan-1, and VAP-1 levels were comparable 
in patients with and without PMI at all time points.
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points (p=0.002, p=0.002, and p=0.001, respectively). There were no 
differences in sTM, syndecan-1, or VAP-1 concentrations between PMI and 
non-PMI patients. The potential correlations between TnT, IL-6, and EG 
markers in patients with and without PMI were tested with Spearman’s rho. 



























Preoperative IL-6 correlated positively with preoperative, 6h postoperative, 
and 24h postoperative TnT in PMI patients (p=0.05). Furthermore, 24-hour 
postoperative sTM correlated positively with preoperative and 6-hour, and 
24-hour postoperative TnT (p=0.05) in PMI patients. In patients without 
PMI, sTM and TnT levels correlated positively preoperatively (p<0.001), 6h 
postoperatively (p=0.001) and 24h postoperatively (p<0.001).
The highest values of each marker were used in the analysis. None of the 
EG markers were predictive for PMI. IL-6 predicted PMI with an AUC (95% 
CI) of 0.69 (0.54-0.85) (p=0.02). The best cut-off value for IL-6 was 0.24 












ESMOLOL FOR PERIOPERATIVE CARDIAC PROTECTION
The characteristics of the three included studies are summarized in Table 11.
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Table 11.
Outcomes n (%) Esmolol Control Esmolol Control Esmolol Control
MI 0 NR NR
NR NR
NR NR NR NR NR NR
0 0 NR NR NR NR
0 0 NR NR NR NR
0 NR NR NR NR
NR NR NR NR NR NR
1 NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR 0 0 0
NR NR 0
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
NR NR NR NR NR NR
¶
The studies included a total of 196 patients, of whom 101 received esmolol and 
96 received control drug or placebo. Placebo was given to 66 of 96 controls 
(68.8%); the remaining 30 patients received diltiazem. In a study by Balser 
and colleagues, one patient was included at two separate times and at both 
times was randomized to receive the control drug; consequently, from this 
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study 64 patients were taken into analysis. However, outcome measures were 
analyzed and reported using 63 individual patients. All studies investigated 
a cohort from a single center and had an inadequate sample size to reach 
Data synthesis and risk of bias
The results of meta-analysis are graphically presented in Figures 6A and 6B 
and summarized in Table 12. Figures 6A and 6B also present the assessed 
risk of bias of the studies. 















PMI 2 ¶ 0
1 0/11 ¶ NA NA
2 ¶ 0




(38.1%), mostly regarding the blinding of participants and personnel. All 
the incidence of AKI or composite of adverse renal events. Furthermore, regarding 
the adverse reactions potentially associated with beta blocker treatment, none 
of the studies reported the incidence of bronchospastic symptoms, neurologic 
sequelae, stroke, or serious infection/sepsis. E-mail enquiries to the authors 
missing outcome measures was not available.
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Completeness of reported data 
The calculated data completeness scores are presented in Appendix 7. Initially, 
there was disagreement regarding 19 of the 108 registered data items, mostly 
considering the reported outcome measures. All discrepancies were resolved 
(range 18 to 22) of a maximum of 38. Generally, the studies reported 55.3-
were most frequently missing. None of the studies reported the effect of 
esmolol on 30-day survival.
effect was only about 10% of the optimal information size of 1000 participants, 
required to detect a 20% relative change, in case that median control group 





Perioperative myocardial infarction is a common complication in patients 
undergoing non-cardiac surgery in a Finnish tertiary care hospital, especially 
in patients with cardiac risk factors. The incidence of PMI in a cohort of 
unselected patients aged over 50 years was 7%. Patients undergoing 
vascular surgery were at a particularly high risk for perioperative cardiac 
complications, with an 11% incidence of PMI. PMI was associated with a 
troponin elevation without other ischemic signs or symptoms was associated 
with a twofold increase in 90-day mortality. Only 20% of PMI patients had 
ischemic symptoms, and therefore, without systematic ischemia monitoring 
the majority of PMIs would remain undiagnosed. The Gupta cardiac risk 
calculator predicted PMI, thus, the use of this index in preoperative evaluation 
may aid in identifying the patients with increased perioperative cardiac 
risk. However, the predictive ability of the index in the current cohort was 
substantially lower than in the development and validation cohorts in the 
USA (an AUC of 0.72 versus 0.88 and 0.87, respectively). The reason for 
suboptimal performance may be in the design of the index. The Gupta cardiac 
risk calculator was developed using statistical regression-based techniques 
that consider only a limited number of risk factors and assume a linear 
relationship between the risk factors and the outcome of interest. However, 
in practice, the risk for an adverse cardiovascular event depends upon a 
complex interaction between the different risk factors, and thus, the risk 
Furthermore, the Gupta cardiac risk calculator was developed and validated 
in a cohort in which PMIs were diagnosed based on clinical suspicion. Since 
no routine cardiac biomarker monitoring was used, this probably led to an 
underestimation of the number of PMIs (Bilimoria et al., 2013).
Postoperative transient myocardial ischemia is a strong predictor for 
development of PMI. The risk for PMI increases in conjunction with increasing 
ischemic load. In this study, one-third of vascular surgery patients with high 
perioperative cardiac risk had postoperative ischemic episodes detectable 
patients with postoperative ischemia than in those without. Cumulative 
ischemic load had an excellent sensitivity in the prediction of PMI. However, 
IL was not associated with rising or falling troponin values, suggesting 
myocardial injury and cardiac enzyme release. It has been demonstrated that 
even minor (below the upper reference limit) cardiac troponin elevations are 
associated with worse survival after non-cardiac surgery (Devereaux et al., 
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2012). This study did not record changes in troponin level below the upper 
reference limit, and thus, it is possible that the association between transient 
ischemic episodes and minor troponin leakages was missed. Currently, 
perioperative troponin surveillance is highly advocated (Mauermann et al., 
2016). Whether more frequent or continuous perioperative monitoring 
of hemodynamic parameters, oxygenation, and ECG adds sensitivity and 
outcome needs to be investigated in future trials.
The pathophysiology of PMI is not completely understood. Although 
the majority of patients who sustain PMI have either moderate or severe 
coronary artery stenoses, stable obstructive coronary artery disease does 
not necessarily increase the risk for perioperative cardiac complications 
(Sheth et al., 2015). However, PMI may develop in the absence of clinically 
 et al., 2015). Considering the partly 
hereditary nature of endothelial function and its independent association 
with development of acute coronary syndromes, acute endothelial glycocalyx 
injury and subsequent dysfunction could be a critical step in determining 
the patients who are susceptible to PMI. Nevertheless, the current study was 
elevated plasma concentrations of EG markers, and PMI. However, systemic 
with maladaptive responses of the endothelial glycocalyx, (Joffre et al., 2020), 
it is possible that the present study simply failed to demonstrate the potential 
endothelial injury of PMI patients, because of the inadequate power of the 
individual hemodynamic targets, for perioperative cardiac protection was 
investigated in a systematic review and meta-analysis. The aim of the study 
clinically relevant 30-day postoperative outcomes. The results showed that 
esmolol reduced postoperative myocardial ischemia, but its potential effect 
on increased bradycardia or hypotension remained unclear. However, as only 
few studies on short-acting intravenous beta blockade in non-cardiac surgery 
exist, the study was unable to determine the effects of this intervention on 
clinically relevant postoperative outcomes, such as mortality. The lack of the 
studies may be partly be due to challenges in conducting the perioperative 
monitoring needed to safely administer intravenous beta blockers. As shown 
in Study II, postoperative cumulative ischemic load was strongly associated 
with development of PMI and combined with heart rate and blood pressure 
monitoring could provide a way to safely target such treatment. Recently, 
several manufacturers have launched light, wireless hemodynamic monitoring 
devices. In the future, improved routine perioperative monitoring may 
enable larger clinical studies on the effects of intravenous beta blockade on 
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INCIDENCE AND PROGNOSIS OF PERIOPERATIVE 
MYOCARDIAL INFARCTION IN A FINNISH TERTIARY CARE 
UNIVERSITY HOSPITAL
Major cardiac complications after non-cardiac surgery are common and are 
associated with substantial mortality and increased costs of medical care 
(London, 2009). The observed incidence of PMI in our Finnish single-center 
series corresponds with observations of other large-scale studies (Devereaux 
et al., 2011; Devereaux et al., 2008; Nagele et al., 2013; van Waes et al., 2013). 
One perioperative myocardial ischemic complication has been estimated to 
cost nearly 10 000 USD (Mackey et al., 2005), and in the context of the current 
results (Study I) this translates to excess costs of nearly one million euros 
per year in Meilahti Hospital alone. The risk for major perioperative cardiac 
complications varies largely between individual patients being the highest 
burden of cardiovascular diseases carried by many of these patients. According 
to a study by Hertzer et al. (1984), the proportion of vascular surgery patients 
with healthy coronary arteries can be as low as 8%. In the current study, 
11% of the patients undergoing vascular surgery sustained PMI, which is in 
 et al., 2004; Borges et al., 2013). 
Clinical presentation of PMI is often asymptomatic, or the symptoms are 
will likely lead to several missed PMIs. Retrospective, register-based studies 
without systematic ischemia monitoring have consistently reported lower 
incidences of PMI than prospective trials, (Udeh et al., 2014; Ghaferi et al., 
2009; Menendez et al.
diagnostics of perioperative myocardial ischemia. The same observation was 
made in this study when comparing the cohorts with and without systematic 
measured perioperatively only in 22% of the patients without systematic 
ischemia monitoring and three PMIs were diagnosed. 
The 90-day mortality after PMI was 29.6%. The mortality rate is high 
relative to previous prospective trials (Devereaux et al., 2011; Devereaux et 
al., 2012; Borges et al., 2013). The majority of deaths occurred during the 
in-hospital mortality after surgery in Finland is low compared with other 
European countries (Pearse et al., 2012). However, based on the results of 
the current study, perioperative cardiac complications seem to substantially 
worsen postoperative outcome. As the population ages and comorbidities 
Despite overall advancements in perioperative care, PMI incidence and 
past decades (von Knorring, 1981). To improve the prognosis, perioperative 
cardiac risk assessment and more intense monitoring of high-risk patients 
should become an integral part of perioperative care. As perioperative 
85
myocardial ischemia is most commonly asymptomatic, routine troponin 
measurements should be applied. However, also useful would be identifying 
from such monitoring. Perioperative cardiac risk indices are feasible and 
despite their limitations, discriminate relatively well between patients with 
high and low cardiac risk. In the current study (I), the Gupta cardiac risk 
calculator predicted PMI with an AUC of 0.73 (95% CI: 0.64-0.81). The best 
3.01 (95% CI: 2.02-4.49), respectively. The low sensitivity may be explained 
by the different ischemia monitoring strategies in the current study and in the 
development and validation studies by Gupta and colleagues. In those studies, 
PMIs were diagnosed based solely on clinical suspicion, which probably has 
led to an underestimation of the number of PMIs. Of note, the risk index did 
not predict the incidence of postoperative myocardial ischemia, as also seen 
in Study II. Finally, if routine troponin monitoring is to be implemented into 
clinical practice, cooperation between cardiologists and internists needs to 
be strengthened to ensure so that patients with perioperative myocardial 
ischemia will be appropriately assessed and treated, when indicated.
SILENT PERIOPERATIVE MYOCARDIAL ISCHEMIA
by ST-segment deviation in Holter monitoring, was investigated (Study II) 
Earlier studies have demonstrated that prolonged postoperative myocardial 
ischemia is associated with development of cardiac complications and 
mortality (Frank et al., 1990; Ganz et al., 1994; Landesberg et al., 1993; 
Landesberg et al., 2001). However, the subject has not been investigated 
further, and it is unclear whether early recognition and management of this 
type of ischemia affect survival. In addition to investigating the prognostic 
aspects necessary for feasible monitoring at the surgical ward, with the 
objective that continuous monitoring of hemodynamic data, oxygenation, 
and ECG alongside cardiac biomarker measurements could become routine 
in patients with high cardiac risk.
Postoperative ischemia was common; one-third of patients had ischemic 
episodes after undergoing peripheral arterial surgery. All the ischemic 
episodes were of the ST-segment depression type, and over 80% of the 
ischemia was asymptomatic. The cumulative ischemic load strongly predicted 
development of PMI with an AUC of 0.87 (95% CI: 0.75-0.99). The best cut-
and 3.83 (95% CI: 2.36-6.23), respectively. The high sensitivity implies that 
and is in accordance with earlier observations (Landesberg, 2005).
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Patients sustaining PMI typically have a stable multi-vessel coronary 
artery disease (Biccard and Rodseth, 2010). Perioperative hemodynamic 
disturbances, such as tachycardia and hypotension, mental stress, and 
postoperative procoagulatory state may cause the stable disease to become 
unstable. It was observed in the current study (II) that most of the 12 
ECG leads showed ischemic changes at least at some point of monitoring. 
Stress-induced ST-segment depression type of ischemia usually affects a 
substantial part of the subendocardium (Ellis et al., 1996), and it is impossible 
to pinpoint the culprit vessel. Considering this, the more ECG leads used 
for postoperative ischemia monitoring, the better the ischemia detection 
sensitivity. However, 12-lead Holter devices are usually too complex and 
impractical for everyday routine use. Despite a precordial lead V5 being the 
most commonly used in three-lead ECG devices, V4 had a better ischemia 
detection sensitivity in the current study, both at the beginning of and at 
the peak ischemia (51.4% vs. 24.7% and 45.7 vs. 17.4%, respectively). The 
best ischemia detection sensitivity was acquired with the combination of 
with earlier studies (London et al., 1988; Martinez et al., 2003) and support 
the observation that combining two precordial leads enhances ischemia 
detection sensitivity. Furthermore, the optimal combination for three-lead 
ECG should perhaps be re-evaluated.
Although a 12-lead Holter device is superior in ischemia detecting 
sensitivity (Landesberg, 2005), it might be too complex for routine everyday 
use. To be feasible for large-scale use in low-acuity setting, the monitoring 
device should be light, relatively small, and easy to assemble and disassemble. 
The number of leads should be reduced to a minimum offering adequate 
ischemia detection sensitivity. However, since lead detachment and artifacts 
are common in the use of Holter monitoring, at least two precordial leads are 
probably needed to ensure satisfactory sensitivity. To enable postoperative 
mobilization, monitoring devices should ideally be wireless. Furthermore, 
the monitoring data should be available on a daily basis and an alarm should 
be triggered by ischemia. Studies have shown that asymptomatic ischemia 
release (Frank  et al., 1990; Landesberg et al., 1993; Landesberg et al., 2001), 
and timely detection and management of ischemia would prevent further, 
potentially more serious complications. 
As postural changes are the most common reason for false-positive 
ischemic alarms, (Adams and Drew, 2002), an integrated motion sensor 
would improve the accuracy of ST-segment analysis. This was tested in the 
segment deviation could not been found. Moreover, postural changes did 
not trigger false alarms. However, the algorithm was tested with only with 
a very small number of patients, and thus, the result needs to be re-tested 
and validated in a larger cohort.
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SYSTEMATIC ISCHEMIA MONITORING VS. ROUTINE 
CLINICAL PRACTICE
Without systematic perioperative ischemia monitoring the majority of 
perioperative cardiac complications will go undiagnosed. As discussed earlier 
in this section, register-based studies without systematic measurements of 
rates of PMI than prospective studies. Many physicians thus seem to be 
unaware of the high incidence and poor prognosis of perioperative myocardial 
ischemia and, perhaps more importantly, have been reluctant to screen it 
since treatment recommendations or guidelines have not been available. This 
study demonstrated that physicians seldom order perioperative troponin 
measurements, even in high cardiac risk patients (Study I). In the cohort 
with routine perioperative care, troponins were measured in only 39 patients 
(22%), three (1.7%) of whom sustained PMI. The patients underwent more 
urgent or emergency operations and had a higher 90-day mortality (13.1% 
vs. 7.3%) than patients with systematic ischemia screening. Accordingly, it is 
likely that many perioperative cardiac complications were missed in these 
patients. Furthermore, performing a study may improve the diagnostics 
and treatment of similar patients not enrolled in the study (Hawthorne 
effect). As the participants of the study were treated at the same wards by 
the same physicians, it may be assumed that their monitoring affected the 
treatment of other patients as well. Thus, without the study, probably more 
PMIs would have been missed by physician-initiated ischemia monitoring, 
and the true advantage of systematic ischemia screening might be larger 
than that observed.
To screen a disease, the used screening method applied should be able to 
discriminate high-risk patients, be validated in prospective studies examining 
hard patient-centered outcomes, exhibit incremental value, be of clinical 
utility and improve clinical outcomes. The last point has yet to been shown in 
routine perioperative cardiac biomarker, namely troponin, screening. Because 
perioperative ischemia monitoring differ. According to some expert opinions, 
troponin should be measured both preoperatively and 48-72 hours after 
major surgery in high-risk patients (Kristensen et al., 2014; Thygesen et 
al., 2012). By contrast, the ACC/AHA guidelines state that the usefulness 
of perioperative troponin screening is uncertain, as recommendations on 
management are lacking (Class IIb, Level B) or only recommend measuring 
troponin if signs or symptoms suggestive of myocardial ischemia are present 
(Fleisher et al., 2014). This approach, however, completely dismisses MINS 
PMI or MINS are somewhat inconclusive. Foucrier and colleagues showed 
in 2014 that patients with perioperative troponin elevation not receiving 
term mortality and cardiovascular complications than patients whose 
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 et al., 2014). However, in a study 
after perioperative troponin elevation did not reduce one-year mortality or 
cardiovascular complications (Chong et al., 2012). The problem with routine 
perioperative troponin screening seems to be its inability to differentiate 
between cardiac and non-cardiac causes. It has been shown that even minor 
troponin elevations are associated with worse postoperative outcome 
(Devereaux et al., 2012), and, for example, in the MANAGE trial this has 
been an indication to initiate dabigatran (Devereaux et al., 2018). Although 
dabigatran reduced long-term major vascular complications, it did not reduce 
myocardial infarction or all-cause mortality per se. Furthermore, although 
not life-threatening, dabigatran caused some considerable bleeding problems 
(Devereaux et al., 2018). Accordingly, the heterogeneity among the results 
the issue that intervention has been targeted to patients who actually do 
not need it or may even be harmed by it. 
Despite both MINS and PMI being associated with substantial mortality, 
only few operative units have perioperative troponin monitoring as a routine 
clinical practice. In fact, reluctance exists in measuring troponin in surgical 
patients, most likely because interpretation of slightly elevated values is 
marked as in non-operative AMI. However, without perioperative ischemia 
monitoring we will miss approximately 60% to 80% of PMIs and up to 90% of 
MINSs. While looking solely at the costs of perioperative troponin monitoring, 
Buse and colleagues estimated the incremental cost of avoiding missing a 
MINS event as 1632 CAD (2015 Canadian dollars). The cost-effectiveness of 
troponin monitoring was higher in patients with increased cardiac risk, the 
incremental cost being 1309 CAD (Buse et al., 2018). By comparison, cost of 
avoiding a breast or cervical cancer thanks to screening is over 10-fold (14 
396 CAD and 18 176 CAD, respectively) (Devereaux and Szczeklik, 2019). 
Finally, the most important goal of perioperative ischemia monitoring is to 
reduce postoperative morbidity and mortality. As the Western population 
is rapidly ageing, prevention, detection, and treatment of perioperative 
cardiac complications is more relevant than ever. Given that the vast majority 
of prognostically important myocardial ischemia and infarctions will go 
with interventions, perioperative ischemia monitoring should be conducted 
for patients with cardiac risk factors undergoing major surgery. Combining 
pre-existing comorbidities with intraoperative adverse events may improve 
the prognostic value of postoperative troponin monitoring.
perioperative troponin screening. For these patients, troponin should be 
measured both preoperatively and after surgery to differentiate perioperative 
myocardial injuries from chronic troponin elevations. Patients with MINS 
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Finally, cardiac biomarker screening in low-risk patients is not useful since 
perioperative mortality in this group is quite limited (Beattie et al., 2012). 
ROLE OF ENDOTHELIAL GLYCOCALYX INJURY AND 
SYSTEMIC INFLAMMATION IN PERIOPERATIVE CARDIAC 
COMPLICATIONS
The pathophysiology of perioperative myocardial injury is not completely 
understood. Clean coronary arteries do not necessarily protect from the 
complication, and, on the other hand, patients with severe coronary artery 
disease may undergo a major surgery without any problems (Sheth et al., 
2015). Elucidating the pathophysiological mechanisms of perioperative 
methods. Considering the systemic nature of endothelial dysfunction and 
its central role in the pathogenesis of atherosclerosis, it seems logical that 
endothelial injury would be associated with development of perioperative 
cardiac complications as well. Furthermore, many factors associated with 
damage the endothelial glycocalyx. Rhem and colleagues showed in 2007 that 
endothelial glycocalyx injury may occur after major aortic surgery, causing 
the components of the glycocalyx to leak into circulation. Moreover, using 
an animal model the authors demonstrated that the plasma-measurable 
components of glycocalyx (syndecan-1 and heparan sulfate) originated from 
coronary vessels (Rhem et al.
association of endothelial dysfunction with acute, nonoperative coronary 
syndromes, (Bonetti et al., 2003; Gokce, 2011; Suwaidi et al., 2000), this study 
the highest value of IL-6 predicted PMI with an AUC (95% CI) of 0.69 (0.54-
0.85), (p=0.02). The best cut-off value for IL-6 was 0.24 pg/L with sensitivity, 
3.56 (1.65-7.65), and 0.55 (0.32-0.95), respectively. None of the measured 
components of the glycocalyx (sTM, syndecan-1, and VAP-1) were predictive 
of PMI. However, in PMI patients 24-hour postoperative sTM correlated 
positively with preoperative and 6- and 24-hour postoperative TnT (p=0.05). 
Currently, there are no other reports on the role of endothelial dysfunction 
in the development of cardiac complications in non-cardiac surgery. With 
regard to a nonoperative setting, high plasma levels of sTM have been shown 
to be associated with acute ST-segment elevation myocardial infarction 
(STEMI), and in the same patients, high syndecan-1 levels were associated 
with heart failure and short- and long-term mortality (Ostrowski et al., 2013). 
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Furthermore, Bro-Jeppesen and colleagues demonstrated that sustained EG 
injury is related to the severity of post-cardiac arrest syndrome and baseline 
IL-6 levels were correlated with EG activation and endothelial cell injury in 
patients with severe myocardial damage (Bro-Jeppesen et al., 2016).
may be suggested. First, the study was relatively small. Because of the 
statistical methods applied, 12 PMI patients had to be excluded from the 
analyses. If mixed model analysis had been used, six of these patients, with 
only 6-hour postoperative or 24-hour postoperative samples missing each, 
could have been included, thus increasing the statistical power of the study. 
Second, it is possible that the timepoints of EG marker measurement were 
not adequate to cover the true perioperative kinetics of the markers. The 
markers were chosen to be measured preoperatively and at 6 hours and 24 
hours postoperatively to investigate the direct effect of surgery on endothelial 
function. However, it is possible that perioperative endothelial injury occurs 
later than this. Finally, it is possible that circulating plasma components of 
endothelium, and the FMD test, for instance, might have been better suited for 
A small study by Manchurov and colleagues showed that remote ischemic 
preconditioning (RIPC) before pPCI clearly improved endothelial function in 
patients with acute myocardial infarction (Manchurov et al., 2014). To better 
perioperative cardiac protection by affecting the integrity of endothelium, 
further investigation on the association of endothelial glycocalyx injury 
hypothesis-generating preliminary evidence that needs to be re-evaluated 
in future larger studies.
ROLE OF ESMOLOL IN PERIOPERATIVE CARDIAC PROTECTION
According to current evidence, the adverse effects of perioperatively started 
(Wijeysundera et al., 2014). An alternative is offered by using drugs with 
short half-life and with the ability to be titrated according to individual 
hemodynamic targets. Esmolol is an ultra-short-acting beta blocker with 
a plasma half-life of two minutes and a washout time of approximately 
nine minutes after stopping infusion (Fita et al., 1999). Because of these 
properties, esmolol seems suitable for prevention of myocardial ischemia 
in the perioperative period, when it is sometimes, for example, in the case 
of bleeding, necessary to immediately interrupt the administration of the 
drug. A couple of small, underpowered randomized controlled trials have 
(Raby et al., 1999; Urban et al., 2000). Furthermore, in 2010, Landoni and 
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colleagues conducted a systematic review and meta-analysis to determine 
the clinical impact of esmolol on patients undergoing non-cardiac surgery 
(Landoni et al., 2010), and in the following year, Yu and colleagues revisited 
this subject with a meta-analysis including more studies (Yu et al., 2011). 
These previous studies demonstrated that esmolol seems to reduce myocardial 
ischemia, and the adverse effects, namely bradycardia and hypotension, can 
be reduced when the drug is given as a continuous infusion (Landoni et 
al., 2010; Yu et al., 2011). However, data regarding the effect of esmolol on 
patient-centered outcomes, such as mortality, and on non-cardiac organs 
are limited. This study aimed to investigate these subjects by means of a 
systematic review and meta-analysis. Compared with the earlier studies, 
only studies reporting postoperative follow-ups and outcomes were included. 
The number of eligible studies and the number of patients included in these 
studies was low causing the meta-analysis to be inadequate in statistical 
results, esmolol seemed to reduce myocardial ischemia, but its effect on 
major postoperative cardiac and non-cardiac complications, such as PMI, 
AKI, or stroke, and mortality remains unclear. Furthermore, the potential 
association of esmolol with increased bradycardia and hypotension could 
question with a larger statistical power, as the meta-analyses also included 
studies with only intraoperative esmolol administration and follow-up, thus 
having a much larger number of eligible studies (3 vs. 32 vs. 67). In both of 
the earlier meta-analyses, the majority of the included studies investigated 
the effect of esmolol on controlling the hemodynamic responses associated 
with laryngoscopy and endotracheal intubation and included rather healthy 
patients. Landoni and colleagues concluded that esmolol did not increase 
episodes of bradycardia and hypotension (Landoni et al., 2010). However, 
the study by Yu and colleagues showed that esmolol was associated with an 
increase in incidence of unplanned hypotension, especially when administered 
in larger bolus doses (Yu et al., 2011). The potential cardioprotective effects 
of esmolol are likely to be acquired with a small initial dose and a continuous 
infusion, and esmolol has the potential to be both effective and safe in the 
prevention of perioperative myocardial ischemia. However, randomized 
controlled trials with higher risk patients, longer duration infusions, and 
and safety of esmolol in perioperative cardiac protection.
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LIMITATIONS
This study has some important limitations that should be considered when 
interpreting the results.
First, this was a single-center study and the vast majority of the patients 
underwent surgery in general anesthesia. Therefore, the results are not 
necessarily generalizable to all Finnish surgical patients, and the effect 
of anesthetic technique (general vs. neuraxial anesthesia) on myocardial 
ischemia could not be investigated. 
 Despite the research group working outside hours and treating physicians 
also participating in the recruitment of patients, the planned 24/7 recruitment 
coverage was not attained in Study I. To make the cohort more representative, 
routinely collected clinical data of patients whose consent was missed 
during the recruitment and who did not decline the use of their data, were 
analyzed and compared with the data of the patients with systematic ischemia 
monitoring. With this approach, the challenges with recruitment offered an 
opportunity to compare the postoperative outcome of patients receiving 
systematic ischemia screening with the outcome of patients receiving standard 
care. Due to differences in recruitment and data collection the comparison 
of the two groups remained descriptive. 
The aim of Study II was to investigate the feasibility of continuous Holter 
monitoring in detecting postoperative myocardial ischemia and the ability 
of cumulative ischemic load in predicting PMI. Due to the small number of 
patients, the study was, however, statistically underpowered to build a model 
that would support the use of a cumulative IL as an automated ischemia alarm. 
Furthermore, Holter monitoring was initiated only after the surgery, and it 
is therefore possible that prognostically important pre- and intraoperative 
events were missed.
The limitations of Study I affect the results of the laboratory substudy 
(III) as well. Furthermore, because of the statistical methods applied, 12 
PMI patients with missing blood samples had to be excluded, decreasing 
the statistical power of Study II. Secondly, the observational design of Study 
should merely be considered as hypothesis-generating preliminary evidence 
regarding the potential association of endothelial glycocalyx injury with PMI, 
Finally, because of the low number of eligible studies and the small number 
of patients included, the statistical power of the systematic review and meta-
the review included studies comparing esmolol with placebo and studies 
comparing esmolol with another drug. This approach may have affected the 
results of the meta-analysis. According to the results of Study IV as well as the 
results of the earlier studies (Landoni et al., 2010; Yu et al., 2011), intravenous 
esmolol seems promising in the prevention of myocardial ischemia. Whether 
this intervention is safe and has an impact on postoperative outcome requires 
investigation in adequately powered trials.
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FUTURE IMPLICATIONS
are common in patients aged over 50 years, especially if they have pre-existing 
mortality. Increasing evidence suggest that dismal prognosis of PMI may be 
or antiplatelet therapy, and this speaks in favour of routine perioperative 
ischemia screening. However, the screening of patients with low cardiac risk is 
not useful. Cardiac risk assessment should be an integral part of preoperative 
evaluation, and the use of perioperative cardiac risk indices and functional 
capacity indices (i.e. Duke activity status index) may add to the accuracy 
for patients with cardiac risk factors (Squizzato et al., 2020). Additionally, 
clinical tests, namely cardiac stress test, can help to differentiate between 
intermediate and high-risk patients (Augoustides et al., 2013). 
In addition to the conventional risk factor assessment, in the future we 
may be able to estimate patients’ cardiac risk at the cellular or molecular 
plays a central role in the process. Furthermore, endothelial dysfunction is 
associated with the development of atherosclerotic complications (Bonetti 
et al., 2003). The association of an acute endothelial dysfunction with PMI 
was investigated in this thesis, and although the results were inconclusive, 
soluble thrombomodulin correlated with perioperative TnT indicating 
that the subject should be investigated in future larger trials. Contrary to 
endothelial markers, a perioperative rise of interleukin-6 was associated with 
accordance with this observation, Handke and colleagues recently published 
a study where they demonstrated a perioperative rise of the monocyte 
activation marker presepsin in patients who had sustained cardiovascular 
after non-cardiac surgery. Furthermore, the authors demonstrated that 
preoperatively elevated presepsin predicted MACCE after surgery and even 
 et al., 2019). Although the 
study was small and has some limitations, it supports the hypothesis that 
cardiovascular events and modulation of this could comprise a new target 
for prevention.
perioperative cardiac complications. After several publications emerged 
from the VISION cohort, (Devereaux et al., 2012), a shift in terminology from 
PMI to MINS has occurred. In 2018, MINS was established as a diagnosis 
Cardiology clinical practice guidelines. Despite the clear established linkage 
between postoperative cardiac troponin elevations and increased mortality, 
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it is important to note that postoperative troponin elevations can be due 
to various etiologies, some of which are non-ischemic, such as sepsis or 
chronic kidney disease. Furthermore, a large proportion of high-risk surgical 
patients have preoperatively elevated troponin levels (Nagele et al., 2013). 
Even in diseases originating outside the heart, elevated troponin has been 
linked to poorer outcome (Martins et al., 2018; John et al., 2010). Without 
knowledge of preoperative baseline value, postoperative troponin elevation 
Currently, clinical practices regarding the timing of perioperative troponin 
measurement vary markedly, and this might have affected the results of some 
of dabigatran following MINS appeared to be mainly due to a reduction in 
non-hemorrhagic stroke, it is possible that at least a subset of patients had non-
ischemic myocardial injury and troponin elevation (Devereaux et al., 2018). 
However, the authors succeeded in introducing a new intriguing strategy 
to improve the postoperative outcome of a large and previously neglected 
group of patients and the study opens the door for further investigations. 
Regarding prevention of MINS, Ekeloef and colleagues recently published 
an interesting report on the effect of remote ischemic preconditioning on 
myocardial injury in emergency hip fracture surgery (Ekeloef et al., 2019). 
The authors showed that RIPC reduced the risk of perioperative myocardial 
injury and infarction in a cohort of 648 patients with cardiovascular risk 
factors. The study was too underpowered to draw conclusions on several 
clinically important outcome measures, such as 30-day mortality, and the 
results of the long-term effect of RIPC are not yet available. RIPC seems an 
attractive option for perioperative cardiac protection as it is inexpensive 
(Hausenloy et al., 2015). However, prior to a change in practice, future larger 
studies are needed to elaborate the effect of RIPC on cardiovascular and other 
clinically important outcomes after non-cardiac surgery. Despite promising 
cardiac surgery have not found any effect on clinical outcomes, including 
myocardial infarction and mortality (Hausenloy et al., 2015; Hausenloy et 
al., 2007; Meybohm et al., 2015).
in preventing cardiac complications in non-cardiac surgery, perhaps due to its 
endothelial stabilization properties (Putzu et al. 2018). The recently updated 
ESC/EAS guidelines for the management of dyslipidemias recommend an 
goal of < 1.4 mmol/L in secondary prevention for patients at very high 
cardiovascular risk (Mach et al., 2020). However, in real-world clinical practice, 
this ambitious goal may be hard to achieve (Dykun et al., 2020). Recently, a 
new class of lipid-lowering drugs, PCSK9 inhibitors, has become available. 
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may reduce cardiovascular events in line with the LDL-cholesterol reduction 
achieved (Mach et al., 2020). However, considering the costs of PCSK9 inhibitor 
treatment and the lack of data on long-term safety, the drugs are not yet in 
everyday use (Mach et al., 2020). Evidence regarding other cardiovascular 
medications is inconclusive and mostly limited to risk-adjusted observational 
studies. However, recently some large RCTs have demonstrated that surgical 
alone or combined with aspirin (Devereaux et al., 2018; Bonaca et al. 2020). 
Clinicians may consider initiating treatment with of angiotensin-converting 
enzyme inhibitor, antiplatelet and/or anticoagulant, or beta blocker based 
on individual assessment. Beta blockers should not be started preoperatively 
for beta blocker-naïve patients without careful titration of the dose according 
to heart rate and blood pressure. Especially when dual-pathway inhibition 
of bleeding. Finally, if patients with MINS or PMI demonstrate recurrent 
instability, coronary angiography should be considered. Again, the potential 
prevent MINS and PMI and to improve the outcome of patients sustaining these 
complications, the management of MINS and PMI should be based on the best 
clinical practices available today. First, we should preoperatively recognize 
the high-risk patients. In the future, we might be able to use information on 
but in the meantime, assessment should be based on clinical cardiovascular 
risk factors. Perioperative troponin measurements should be considered for 
patients deemed at high risk preoperatively and undergoing major surgery. 
It is important to measure the preoperative troponin value in order to be 
able to distinguish chronic troponin elevations from acute myocardial 
injuries. However, as discussed earlier, preoperative assessment of risk 
can be very different from postoperative likelihood of developing MINS 
or PMI, and incorporating assessment of intraoperative events, namely 
postoperative troponin monitoring. In terms of preventing perioperative 
cardiac complications, accurate monitoring of intra- and postoperative 
hemodynamics and treatment of hypotension, tachycardia, hypoxia, and 
hypothermia is effective. Moreover, low nadir hemoglobin value associated 
with development of PMI in the patient material of this thesis, emphasizes 
avoidance of excess blood loss during surgery. Patients who sustain MINS or 
PMI should be referred for cardiology consultation, and based on individual 
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CONCLUSIONS
1. Perioperative myocardial infarction is a frequent and serious 
complication (7% incidence, 30% 90-day mortality) in patients 
aged 50 years or older undergoing non-cardiac surgery in a 
Finnish tertiary care hospital. Elderly patients with pre-existing 
cardiovascular diseases are at highest risk for developing 
the complication. The performance of the Gupta cardiac risk 
calculator was fair, and its routine use may help to identify 
2. Asymptomatic postoperative ischemic electrocardiographic 
changes are common in high-risk patients undergoing vascular 
surgery and cumulative ischemic load strongly predicts 
development of myocardial infarction.
3. 
with postoperative troponin release and myocardial infarction. 
The potential association of endothelial glycocalyx injury with 
perioperative myocardial infarction remains unclear, as Study 
III was too underpowered to answer to this question.
4. According to the systematic review and meta-analysis, intravenous 
esmolol, titrated according to individual heart rate and blood 
pressure levels, seems to reduce perioperative myocardial 
ischemia. The published studies were too few and too small to 
determine the safety of this intervention and whether it has an 
impact on clinically relevant, patient-centered outcomes.
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